Autosomal Dominant Nonsyndromic Hearing Loss 25

Mendelian MONDO:0011568 Pathograph 15 Show in embeddings browser Autosomal Dominant Nonsyndromic Hearing Loss Hereditary Hearing Loss

SLC17A8-related autosomal dominant nonsyndromic hearing loss is usually progressive and predominantly high-frequency, with variable onset and age-dependent penetrance. VGLUT3 loads glutamate into inner hair cell synaptic vesicles. Human segregation establishes the gene-disease relationship, but the dominant molecular mechanism remains unresolved. Homozygous null mice lack sound-evoked afferent signaling; homozygous A224V knock-in mice, modeling human A211V, develop inner hair cell bundle disruption followed by ribbon and exocytosis changes. Heterozygous knock-in mice have a much milder phenotype. These models establish complementary experimental findings rather than interchangeable accounts of human disease. The limited human otoacoustic-emission data do not settle whether DFNA25 belongs within the auditory neuropathy spectrum.

Ask OpenScientist

Ask a research question about Autosomal Dominant Nonsyndromic Hearing Loss 25. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

1
Autosomal dominant HP:0000006
Autosomal dominant transmission with age-dependent penetrance. Each child of a heterozygous affected individual has a 50% chance of inheriting the variant; this is not a 50% probability of hearing loss at a specified age. Earlier reported onset in males and a maternal-versus-paternal haplotype pattern arose in one pre-gene-mapping kindred and remain unreplicated modifier hypotheses. Normal hearing at one assessment does not exclude carrier status. Four tested mitochondrial variants were absent, which does not exclude all mitochondrial effects.
Autosomal dominant inheritance
Show evidence (4 references)
PMID:12925340 SUPPORT Human clinical
"The mode of inheritance is autosomal dominant with age-dependent penetrance."
Inheritance mode and the penetrance qualifier together.
PMID:12925340 SUPPORT Human clinical
"In those inheriting the DFNA25-associated haplotype from an affected mother, hearing loss invariably developed by the second decade of life, whereas those inheriting the DFNA25 haplotype from an affected father often maintained hearing levels comparable to those of age-matched control subjects,..."
The parent-of-origin observation, quoted in full so the size and source of the claim travel with it.
PMID:12925340 SUPPORT Human clinical
"None of 4 deafness-associated mitochondrial mutations screened (1555A>G, 7445A>G, Cins7472, and 7511T>C) were found to segregate in the family."
Only the four tested mitochondrial variants were excluded; the study did not sequence the mitochondrial genome or establish the cause of the parent-of-origin pattern.
+ 1 more reference
◈

Mechanistic Hypotheses

2
Presynaptic vesicular glutamate loading failure
presynaptic_glutamate_loading_failure CANONICAL
VGLUT3 deficiency prevents vesicular glutamate loading and auditory afferent activation in homozygous null mice despite preserved vesicle fusion and cochlear amplification. This is an established null-model mechanism and a candidate contributor to human SLC17A8 disease. It does not establish haploinsufficiency or uniform transport loss for dominant variants: A211V retains transport in tested heterologous systems, and human onset and severity vary.
Stereociliary mechanotransduction failure preceding synaptic change
a211v_mechanotransduction_first EMERGING
Homozygous A224V mice develop inner hair cell stereocilia disruption and reduced summating potentials before marked ribbon enlargement and increased sustained exocytosis. This supports a mechanotransduction-first hypothesis in that model. Temporal order does not establish that the bundle lesion causes the synaptic changes, and the dominant human mechanism remains unconfirmed.
?

Discussions and Knowledge Gaps

4
Does either mouse model DFNA25, when both are homozygous and the heterozygote - the genotype a patient actually has - is only mildly affected?
HUMAN MODEL MISMATCH OPEN mismatch_zygosity_of_the_dfna25_mouse_models
Homozygous knock-in mice have progressive impairment but heterozygotes have only mild changes over six months. Lifespan, allele dose, genetic background and species-specific biology may contribute. Null rescue does not select the optimal strategy for dominant human alleles.
Proposed experiments
Lifespan-long auditory phenotyping of heterozygous VGLUT3 A224V mice
dfna25_aged_heterozygous_knockin
Follow heterozygous A224V and wild-type littermates across age with serial ABR, emissions and bundle morphology, accounting for background-related hearing loss.
Supporting outcome
  • A widening deficit would support age-dependent expression in this mouse model, without proving that homozygous pathology transfers to humans.
Refuting outcome
  • A plateau would argue against continued progression under the tested conditions; it would not establish universal tolerance of one allele.
How representative is the absent-emission finding in the original DFNA25 proband?
KNOWLEDGE GAP OPEN gap_why_patient_emissions_are_absent
The detailed primary human observation concerns one proband, while both main mouse models retain emissions. Broader human OAE, cochlear microphonic, ABR, age and exposure data are needed to separate cochlear and neural contributions. Controlled mouse noise experiments can test model susceptibility but cannot establish the cause of human findings.
Proposed experiments
Noise vulnerability in mice carrying one or two VGLUT3-p.A224V alleles
dfna25_noise_vulnerability_by_allele_dose
Expose wild-type, heterozygous and homozygous A224V mice to a controlled acoustic overexposure and compare distortion-product emission loss and threshold shift against unexposed littermates. This is the experiment the knock-in authors name as necessary to determine whether acoustic injury accounts for the discrepancy between mouse and patient emissions.
Supporting outcome
  • Greater emission loss after controlled noise would support genotype-dependent susceptibility in mice and motivate human exposure studies.
Refuting outcome
  • No genotype difference would weaken this model-specific noise hypothesis under the tested exposure; it would not resolve human auditory-neuropathy classification.
How does a vesicular glutamate transporter variant collapse the inner hair cell stereocilia bundle?
KNOWLEDGE GAP OPEN gap_where_the_dfna25_lesion_starts
A224V mice show bundle collapse despite retained transport in heterologous systems and comparable cochlear VGLUT3 immunofluorescence. Proteostasis, trafficking and the Cdh23 background remain candidate contributors. Identifying the mechanism could guide therapy, but a gene-directed intervention might affect both bundle and synaptic consequences.
Proposed experiments
Subcellular localisation and turnover of VGLUT3-p.A224V in inner hair cells
dfna25_vglut3_localisation_in_knockin_hair_cells
Track variant VGLUT3 in knock-in inner hair cells by immunogold electron microscopy and pulse-chase, testing directly whether it accumulates in the soma or apical compartment, whether proteostasis markers are engaged, and whether the cuticular plate cytoskeleton is disturbed before the bundles collapse.
Supporting outcome
  • Accumulation and proteostasis changes preceding bundle collapse would support this candidate mechanism; perturbation and rescue would be needed to test causation.
Refuting outcome
  • Normal localization and turnover would weaken this mechanism without excluding other allele-dependent or background effects.
Do the truncating and splice SLC17A8 alleles cause the same disease as the missense founder allele?
KNOWLEDGE GAP OPEN gap_dfna25_allele_class_heterogeneity
Attached to
Missense, frameshift and splice alleles have unequal human and functional evidence. The frameshift and c.824C>A expression study retested reported alleles. Allelic heterogeneity does not by itself justify splitting a disease, and a normal heterozygous-null mouse does not resolve the human dominant mechanism.
Proposed experiments
Audiometric comparison of missense against truncating SLC17A8 carriers
dfna25_allele_class_audiogram_comparison
Collect audiograms and ages at onset across all published SLC17A8 heterozygotes and compare the founder missense families against the frameshift and splice-donor families, testing whether onset, progression rate and audiometric shape differ by allele class.
Would support
Supporting outcome
  • Overlapping profiles would support shared clinical features without proving a shared molecular mechanism.
Refuting outcome
  • Reproducible differences would support allele-specific prognosis and further mechanistic work, without by themselves requiring separate disease entities.
⚙

Pathophysiology

9
Heterozygous SLC17A8 Variant
The founding c.632C>T (p.A211V) variant segregated in two families with evidence of distant shared ancestry and was absent from 267 controls. Later reports include c.616dupA (p.M206Nfs*4) and c.763+1G>T. The 2016 frameshift report sequenced one proband from an affected pedigree; it did not demonstrate segregation across all eight affected relatives. Predicted truncation and splice disruption do not establish a shared dominant mechanism.
Genetic context SLC17A8 hgnc:20151 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns SLC17A8 (hgnc:20151). hgnc:20151 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: HETEROZYGOUS
Reported disease-associated alleles are heterozygous. The entry does not assign one functional-impact category across missense, frameshift and splice variants: human dominance and normal heterozygous-null mouse hearing do not by themselves distinguish dosage loss, dominant-negative effects or other mechanisms.
Show evidence (4 references)
PMID:18674745 SUPPORT Human clinical
"In two unrelated families, a heterozygous missense mutation, c.632C-->T (p.A211V), was found to segregate with DFNA25 deafness and was not present in 267 controls."
The founding allele, its zygosity, its segregation and its control screening.
PMID:18674745 SUPPORT Human clinical
"The A211 residue is conserved in VGLUT3 across species and in all human VGLUT subtypes (VGLUT1-3), suggesting an important functional role."
The conservation argument the founding paper rests the missense call on.
PMID:26797701 SUPPORT Human clinical
"The novel frameshift mutation, p.M206Nfs*4, in which methionine is changed to asparagine at amino acid position 206, resulted in a termination codon at amino acid position 209."
The 2016 report identified a frameshift in one sequenced proband and predicted truncation; it did not show cosegregation in all affected relatives.
+ 1 more reference
Altered VGLUT3 Function in the Inner Hair Cell
VGLUT3 supports glutamate loading into inner hair cell synaptic vesicles. Null mice lack functional auditory afferent transmission, but human A211V does not abolish uptake or quantal signaling in tested heterologous/autaptic preparations. Central-terminal protein reduction in the knock-in cannot be assumed in cochlear cells: the 2021 study found comparable inner hair cell VGLUT3 immunofluorescence and distribution between genotypes. Variant-specific effects therefore remain important.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
glutamate loading into inner hair cell synaptic vesicles GO:0098700 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves glutamate loading into inner hair cell synaptic vesicles, annotated with neurotransmitter loading into synaptic vesicle (GO:0098700). GO:0098700 is a biological process from the Gene Ontology.
vesicular L-glutamate transport by VGLUT3 GO:0005313 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves vesicular L-glutamate transport by VGLUT3, annotated with L-glutamate transmembrane transporter activity (GO:0005313). GO:0005313 is a molecular function from the Gene Ontology.
inner hair cell synaptic vesicle GO:0008021 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves inner hair cell synaptic vesicle, annotated with synaptic vesicle (GO:0008021). GO:0008021 is a cellular component from the Gene Ontology.
Show evidence (4 references)
PMID:18674745 SUPPORT Model organism
"In the cochlea, VGLUT3 accumulates glutamate in the synaptic vesicles of the sensory inner hair cells (IHCs) before releasing it onto receptors of auditory-nerve terminals."
The normal function of the protein, which is what the disease removes or alters.
PMID:26797701 SUPPORT BACKGROUND Other
"among its isoforms (VGLUT1-3), only VGLUT3 is expressed selectively in the inner hair cells (IHCs)"
Inner hair cell expression provides a basis for nonredundant cochlear function. It does not explain the absence of extra-auditory findings in every carrier.
PMID:34783032 SUPPORT INDIRECT BACKGROUND In vitro / ex vivo
"This variation does not impair the glutamate vesicular accumulation, neither the quantal release nor the quantal content in hippocampal autaptic neurons"
A negative result at the level of transport itself, which is why this entry does not assert that the human missense allele simply stops glutamate loading. Graded IN_VITRO because the measurement is in cultured autaptic neurons.
+ 1 more reference
Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
In the Ruel Slc17a8-null line, calcium-triggered vesicle turnover was preserved at two weeks and surviving ribbons had a normal ultrastructural appearance at three months, while auditory afferent signaling failed. Other null-model studies reported thin or elongated ribbons. The findings differ by study and preparation; they do not establish universally normal ribbon morphology or uniform transport loss in dominant human variants.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
glutamate secretion at the inner hair cell afferent synapse GO:0014047 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased glutamate secretion at the inner hair cell afferent synapse, annotated with glutamate secretion (GO:0014047). GO:0014047 is a biological process from the Gene Ontology.
Show evidence (3 references)
PMID:18215623 SUPPORT Model organism
"We now report that mice lacking VGLUT3 are profoundly deaf due to the absence of glutamate release from hair cells at the first synapse in the auditory pathway."
The release failure stated directly, and its location at the first auditory synapse.
PMID:18674745 SUPPORT In vitro / ex vivo
"Ca(2+)-triggered synaptic-vesicle turnover was normal in IHCs of Slc17a8 null mice when probed by membrane capacitance measurements at 2 weeks of age."
The deliberate negative result that localises the defect to vesicle content rather than to exocytosis. Without it the node would be indistinguishable from a fusion defect.
PMID:18674745 SUPPORT Model organism
"We conclude that deafness in Slc17a8-deficient mice is due to a specific defect of vesicular glutamate uptake and release and that VGLUT3 is essential for auditory coding at the IHC synapse."
The founding paper's own conclusion about the null animal.
Inner Hair Cell Stereocilia Bundle Disruption
Homozygous A224V mice show progressive inner hair cell bundle fusion and collapse with relative preservation of outer hair cell bundles. VGLUT3 is not localized to stereocilia, and the molecular connection is unresolved. Protein misfolding/trafficking effects and interaction with the C57BL/6J Cdh23 background are hypotheses. Comparable inner hair cell immunofluorescence argues against gross protein accumulation but cannot exclude altered turnover or proteostasis.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
inner hair cell stereocilium bundle organization GO:0060122 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased inner hair cell stereocilium bundle organization, annotated with inner ear receptor cell stereocilium organization (GO:0060122). GO:0060122 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:34783032 SUPPORT Model organism
"Scanning electron microscopy examinations demonstrated the collapse of stereocilia bundles in IHCs, leaving those from outer hair cells unaffected."
The bundle finding and its restriction to inner hair cells.
Reduced Inner Hair Cell Receptor Potential
The summating potential is the gross cochlear correlate of the inner hair cell receptor potential, and it is reduced in the knock-in mouse. Because cochlear amplification is intact in the same animals, a smaller receptor potential is being generated from a normal mechanical input - which is what a transduction defect in the inner hair cell looks like from outside.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
mechanotransduction in the inner hair cell hair bundle GO:0050910 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased mechanotransduction in the inner hair cell hair bundle, annotated with detection of mechanical stimulus involved in sensory perception of sound (GO:0050910). GO:0050910 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:34783032 SUPPORT Model organism
"The summating potential was reduced, indicating the alteration of inner hair cell (IHC) receptor potential."
The measurement and the authors' own interpretation of it.
PMID:34783032 SUPPORT Model organism
"These results suggest that DFNA25 stems from a failure in the mechano-transduction followed by a change in synaptic transfer."
The ordering claim that this hypothesis group is built on, stated by the authors as a suggestion rather than a demonstration - which is why the group is EMERGING.
Synaptic Ribbon Enlargement
Homozygous A224V inner hair cell ribbons enlarge markedly at four to six months, with preserved ribbon and synapse counts in the sampled region. This structural change follows early bundle abnormalities. Its causal contribution to hearing loss, including whether it is compensatory, remains unresolved.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:34783032 SUPPORT DIRECT PRIMARY RESULT Model organism
"However, synaptic ribbons became abnormally elongated in knock‐in mice"
Mouse cochlear imaging supports ribbon enlargement, not a measured increase in glutamate secretion.
Increased Sustained Inner Hair Cell Exocytosis
At six months, freshly dissected homozygous A224V inner hair cells show increased sustained exocytic capacitance responses to long depolarizations, with preserved calcium currents and readily releasable pool responses. Capacitance measures membrane fusion rather than vesicular glutamate content or afferent neurotransmission. The change may reflect compensation or extrasynaptic release; it is not established as a cause of hearing loss.
cochlear inner hair cell CL:0000589 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear inner hair cell (CL:0000589). CL:0000589 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:34783032 SUPPORT DIRECT PRIMARY RESULT In vitro / ex vivo
"patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained releasable pool exocytosis"
Ex-vivo patch-clamp measurements in isolated mouse organs of Corti; membrane fusion does not determine glutamate quantal content.
Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
Slc17a8-null mice lack sound-evoked auditory responses while retaining otoacoustic emissions and electrically evoked brainstem responses. Homozygous A224V mice show progressive auditory threshold elevation with preserved emissions. Human otoacoustic-emission data are sparse and differ from these model findings; this node records experimental physiology rather than a universal human diagnostic signature.
type 1 spiral ganglion neuron CL:4023115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves type 1 spiral ganglion neuron (CL:4023115). CL:4023115 is a cell type from the Cell Ontology. cochlear outer hair cell CL:0000601 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cochlear outer hair cell (CL:0000601). CL:0000601 is a cell type from the Cell Ontology.
sensory perception of sound GO:0007605 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased sensory perception of sound (GO:0007605). GO:0007605 is a biological process from the Gene Ontology.
organ of Corti UBERON:0002227 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in organ of Corti, annotated with spiral organ of cochlea (UBERON:0002227). UBERON:0002227 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:18674745 SUPPORT Model organism
"Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses to acoustic stimuli, although auditory brainstem responses could be elicited by electrical stimuli, and robust otoacoustic emissions were recorded."
All three halves of the dissociation in one sentence: no acoustic neural response, preserved electrical response, preserved emissions.
PMID:34783032 SUPPORT Model organism
"Using auditory brainstem response and distortion product otoacoustic emissions, we showed progressive hearing loss with intact cochlear amplification in the VGLUT3A224V/A224V mouse."
The same dissociation in the allele-matched model, and in progressive rather than congenital form.
Secondary Deafferentation of the Inner Hair Cell
Null mice show loss of afferent synapses, spiral ganglion neurons and lateral efferent endings; some neuronal loss precedes hearing onset. Older null cochleae also show inner hair cell and stereocilia degeneration. These observations raise questions about treatment timing, but do not define a human therapeutic window. Rescue studies in post-neonatal null mice remain distinct from dominant human disease.
spiral ganglion neuron CL:0011113 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves spiral ganglion neuron (CL:0011113). CL:0011113 is a cell type from the Cell Ontology.
Show evidence (3 references)
PMID:18674745 SUPPORT Model organism
"Later, the number of afferent synapses, spiral ganglion neurons, and lateral efferent endings below sensory IHCs declined."
The deafferentation itself, and its late timing relative to the functional deficit.
PMID:18215623 SUPPORT Model organism
"The early degeneration of some cochlear ganglion neurons in knockout mice also indicates an important developmental role for the glutamate released by hair cells before the onset of hearing."
The developmental component, which is a different claim from use-dependent loss and is the reason a congenital null and an adult-onset human disease may diverge here.
PMID:40841774 SUPPORT Model organism
"In this study, we analyzed the cochlear structure of aged Vglut3KO mice, revealing significant degeneration of inner hair cells, synapses, and stereocilia."
The structural endpoint in the aged null animal.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Autosomal Dominant Nonsyndromic Hearing Loss 25 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Ear 3
Progressive High-Frequency Sensorineural Hearing Loss High-frequency sensorineural hearing impairment HP:0001757 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is High-frequency sensorineural hearing impairment (HP:0001757), qualified as course progressive. HP:0001757 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:11115382 SUPPORT Human clinical
"we identified a novel dominant locus, DFNA25, for delayed-onset, progressive, high-frequency, nonsyndromic sensorineural hearing loss in a large, multigenerational United States family of Czech descent."
The phenotype as defined at the locus, in the founding kindred.
PMID:18674745 SUPPORT Human clinical
"We have identified SLC17A8, which encodes the vesicular glutamate transporter-3 (VGLUT3), as the gene responsible for DFNA25, an autosomal-dominant form of progressive, high-frequency nonsyndromic deafness."
The same phenotype restated once the gene was in hand.
Postlingual Delayed Onset Postlingual sensorineural hearing impairment HP:0008596 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Postlingual sensorineural hearing impairment (HP:0008596). HP:0008596 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:12925340 SUPPORT Human clinical
"Affected individuals typically manifest a high-frequency, slowly progressive sensorineural hearing loss in the postlingual period."
The abstract explicitly says typically. The primary full text documents an early-onset exception; normal hearing through speech acquisition is not universal.
"In general, autosomal dominant nonsyndromic hearing loss is postlingual, progressive, and high frequency."
General clinical baseline, not a SLC17A8-specific age distribution or exclusion of congenital presentations.
Absent Otoacoustic Emissions HP:6000182 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absent otoacoustic emissions (HP:6000182). HP:6000182 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34783032 SUPPORT INDIRECT BACKGROUND Human clinical
"In contrast, otoacoustic emissions were absent in patients harbouring the p.A211V allele"
Secondary discussion of the 2003 human study. Inspection of that primary full text limits the detailed OAE/ABR observation to the proband; the plural wording is not evidence for prevalence or a universal classification.
Other 1
Absence of Syndromic Features
Show evidence (1 reference)
PMID:28647561 SUPPORT Human clinical
"the clinical information about this family revealed that there are no other symptoms accompanied with HL"
The nonsyndromic statement in a reported dominant family.
🧬

Genetic Associations

1
SLC17A8
Gene: SLC17A8 hgnc:20151 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SLC17A8 (hgnc:20151). hgnc:20151 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
"Variants in this gene segregated with disease in 28 additional members in two families"
The segregation evidence behind the Definitive classification.
"In summary, SCL17A8 is definitively associated with autosomal dominant nonsyndromic hearing loss."
The panel's summary sentence. The gene symbol is transposed in the source record and is quoted as written.
🗃️

External Assertions

1
ClinGen SLC17A8-nonsyndromic hearing loss gene-disease validity assertion
The ClinGen Hearing Loss Gene Curation Expert Panel raised the SLC17A8-autosomal dominant nonsyndromic hearing loss relationship from Strong in 2018 to Definitive in June 2023. Its assessment included at least eight variants in nine probands and segregation in 28 additional relatives. These are counts in that dated evidence assessment, not worldwide case totals or prevalence estimates.
Show evidence (3 references)
"SLC17A8 | HGNC:20151 | nonsyndromic genetic hearing loss | MONDO:0019497 | AD | Definitive"
The expert-panel classification row itself, with gene, disease, inheritance mode and verdict.
"At least 8 unique variants (missense, frameshift, splice site) have been reported in humans in 9 probands"
Counts in the June 2023 ClinGen assessment, not current worldwide totals or a prevalence denominator.
"As a result of this reevaluation, the classification increased from Strong to Definitive due to additional case level evidence"
The expert panel upgraded the relationship from Strong to Definitive in 2023.
💊

Medical Actions

5
Hearing Aids
Action: hearing aid fittingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hearing aid fitting, annotated with Rehabilitation (NCIT:C15315), qualified as medical device hearing aid. NCIT:C15315 is a clinical intervention from the NCI Thesaurus. Ontology label: Rehabilitation NCIT:C15315
Platform: Device
Offer audiologist-fitted amplification and communication support according to hearing thresholds, speech testing and individual preferences. This follows general genetic hearing-loss care; genotype-specific benefit cannot be predicted from the null mouse or an isolated OAE finding.
Show evidence (1 reference)
"customized by an audiologist to the degree and frequency of hearing loss, can be used in individuals with mild-to-severe hearing loss."
General hearing-aid guidance, not a DFNA25 outcome estimate.
Cochlear Implantation
Action: cochlear device implantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is cochlear device implantation, annotated with Surgical Procedure (NCIT:C15329), qualified as medical device cochlear implant. NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Platform: Device
Consider cochlear implantation under standard audiologic candidacy assessment when amplification provides insufficient benefit. Preserved electrically evoked responses in null mice provide mechanistic plausibility, but do not establish human DFNA25 implant efficacy or guarantee preservation of the neural target.
Mechanism Target:
BYPASSES Failure of Auditory Nerve Activation with Preserved Cochlear Amplification — Direct electrical stimulation of the spiral ganglion substitutes for the defective inner hair cell synapse.
Show evidence (1 reference)
PMID:18674745 SUPPORT Model organism
"although auditory brainstem responses could be elicited by electrical stimuli"
The preserved electrical responsiveness that an implant would exploit. Model evidence for a human intervention, so the claim in the description is plausibility rather than efficacy.
Show evidence (1 reference)
"Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear implants"
General habilitation options; no SLC17A8-specific outcome is asserted.
AAV-mediated VGLUT3 Gene Replacement
Action: gene therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is gene therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. Ontology label: Gene Therapy NCIT:C15238
Platform: Gene therapy
Preclinical gene replacement has restored auditory responses in homozygous null mice after neonatal cochlear AAV1 delivery, adult intracisternal delivery through the cochlear aqueduct, and AAV8 injection at five weeks with assessment 27 weeks later. The latter does not demonstrate reversal after treatment of already aged animals. These interventions have not established efficacy in dominant A211V disease; augmentation, suppression or combined strategies require variant-specific testing. No human SLC17A8 interventional study was identified in the reviewed research; the registered NCT01802190 study is observational.
Mechanism Target:
RESTORES Altered VGLUT3 Function in the Inner Hair Cell — Restoring VGLUT3 protein to the inner hair cell addresses the molecular lesion rather than its consequences - in an animal that has none of the protein to begin with.
Show evidence (2 references)
PMID:22841313 SUPPORT Model organism
"Within 2 weeks of AAV1-VGLUT3 delivery, auditory brainstem response (ABR) thresholds normalize, along with partial rescue of the startle response."
The functional rescue, in the null mouse.
PMID:40841774 SUPPORT Model organism
"Auditory brainstem response (ABR) testing demonstrated restoration of auditory function following gene therapy."
Mice were injected at five weeks and evaluated 27 weeks later, so the aged endpoint does not establish efficacy when treatment starts in aged animals.
Show evidence (2 references)
PMID:22841313 SUPPORT Model organism
"These findings represent a successful restoration of hearing by gene replacement in mice, which is a significant advance toward gene therapy of human deafness."
The authors' own framing of how far the result reaches - toward human therapy, not to it.
DOI:10.1126/scitranslmed.abq3916 SUPPORT DIRECT PRIMARY RESULT Model organism
"rescued hearing in adult deaf Slc17A8 −/− mice by restoring VGLUT3 protein expression in inner hair cells"
Primary 2023 adult-null-mouse rescue supporting the CSF-delivery theme in the research report.
Audiologic surveillance and noise protection
Follow hearing serially and adjust rehabilitation as needed. Avoid repeated loud-noise overexposure using general hearing-loss guidance. No SLC17A8-specific surveillance interval or proven genotype-specific noise susceptibility is inferred.
Show evidence (2 references)
"Regular follow up is recommended for all individuals with genetic hearing loss"
General surveillance baseline.
"persons with documented hearing loss should be counseled appropriately and repeated overexposure to loud noises should be avoided."
General precaution; no demonstrated DFNA25-specific disease-modifying effect.
Genetic counseling
Action: Genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Discuss 50% variant transmission per pregnancy, variable onset and penetrance, familial testing and reproductive options. Counseling should respect individual communication and reproductive preferences.
Show evidence (2 references)
"Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic variant to each child."
General autosomal dominant transmission probability, distinct from penetrance.
"Once the pathogenic variant(s) have been identified in the family, prenatal and preimplantation genetic testing for genetic hearing loss are possible."
General reproductive-testing guidance after identification of the familial variant.
🔬

Diagnosis

3
Pure-Tone Audiometry
Audiometric assessment documents and tracks the delayed-onset, progressive, high-frequency-predominant sensorineural hearing loss that defines DFNA25, as a step separate from the molecular testing described in the row below.
audiometric test NCIT:C38036 NCI Thesaurus (NCIT)
pure-tone threshold audiometry LOINC:89015-2 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, left ear, 500 Hz LOINC:89024-4 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, right ear, 500 Hz LOINC:89025-1 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, left ear, 1000 Hz LOINC:89016-0 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, right ear, 1000 Hz LOINC:89017-8 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, left ear, 2000 Hz LOINC:89018-6 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, right ear, 2000 Hz LOINC:89019-4 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, left ear, 4000 Hz LOINC:89022-8 Logical Observation Identifiers Names and Codes (LOINC) hearing threshold, right ear, 4000 Hz LOINC:89023-6 Logical Observation Identifiers Names and Codes (LOINC)
No reference range is recorded: the cited founding-locus report states the loss is progressive and high-frequency-predominant but gives no severity grade or dB cut-off specific to DFNA25.
Show evidence (1 reference)
PMID:11115382 SUPPORT Human clinical
"we identified a novel dominant locus, DFNA25, for delayed-onset, progressive, high-frequency, nonsyndromic sensorineural hearing loss in a large, multigenerational United States family of Czech descent."
States the progressive, high-frequency-predominant audiometric pattern that these measurements document and track over serial audiograms.
Molecular testing of SLC17A8
Combine audiologic assessment, examination for syndromic findings, family history and molecular testing. A hearing-loss multigene panel or genomic testing can identify SLC17A8 alongside overlapping causes. Testing a known familial pathogenic variant clarifies carrier status; audiometry independently measures current hearing and progression.
Show evidence (3 references)
PMID:28647561 SUPPORT Human clinical
"To identify a causative mutation of HL in this family, we performed whole-exome sequencing of 4 family members, 3 affected and an unaffected."
Family exome sequencing identified the splice-site variant; the paper does not state that linkage was unavailable.
PMID:26797701 SUPPORT Human clinical
"In this study, we performed a genetic analysis of 87 unrelated Korean patients with ADNSHL to determine whether the SLC17A8 gene affects hearing ability in the Korean population."
The screened cohort comprised 87 unrelated dominant-hearing-loss probands; the single candidate frameshift does not provide a general diagnostic yield.
"Single-gene testing (sequence analysis of a given gene, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended."
General initial diagnostic strategy; targeted testing for a known familial variant is a separate indication.
Variant interpretation as a distinct problem in this gene
Evaluate each variant using segregation, population data, phenotype and functional evidence. A VUS does not confirm or exclude DFNA25. The 2016 full text found I78V did not cosegregate and A374S also occurred in normal-hearing controls, illustrating why conservation and predictions alone are insufficient. Cell-culture effects of c.616dupA and c.824C>A are functional support, not proof of a shared mechanism or clinical pathogenicity.
Show evidence (3 references)
PMID:34145196 SUPPORT Other
"Although several suspected pathogenic mutations of the SLC17a8 gene have been identified in humans, few studies have confirmed their pathogenicity."
The interpretation problem stated by the authors as their motivation.
PMID:34145196 SUPPORT In vitro / ex vivo
"The c.616dupA mutation in the SLC17a8 gene resulted in a significant decrease in transcriptional activity of mRNA, and the expression of VGluT3 was also reduced. The c.824C>A mutation in the SLC17a8 gene resulted in abnormal VGluT3, although this mutation did not affect the transcriptional..."
Two alleles in one gene with two different molecular consequences, measured in cell culture.
"The identification of variant(s) of uncertain significance cannot be used to confirm or rule out the diagnosis."
General variant-interpretation guidance.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Autosomal Dominant Nonsyndromic Hearing Loss 25:

Presbycusis and noise-induced hearing loss
Overlapping Features Age-related and noise-related hearing loss can resemble DFNA25. Pedigree information and molecular testing help distinguish causes, while acquired exposures and genetic disease may coexist. Audiogram shape alone is insufficient.
Show evidence (2 references)
PMID:12925340 SUPPORT Human clinical
"It is difficult to differentiate delayed-onset high-frequency sensorineural hearing loss inherited as a simple mendelian trait like DFNA25-associated hearing loss from that due to noise exposure or presbycusis, disorders that may also have a genetic component."
The difficulty stated as the study's own conclusion.
PMID:18674745 SUPPORT BACKGROUND Human clinical
"Autosomal-dominant sensorineural hearing loss is genetically heterogeneous, with a phenotype closely resembling presbycusis, the most common sensory defect associated with aging in humans."
The same resemblance stated for the dominant class DFNA25 belongs to.
🔬

Clinical Trials

1
NCT01802190 NOT_APPLICABLE TERMINATED
Observational genetic screening and phenotypic characterization of SLC17A8/DFNA25 and POU4F3/DFNA15 in dominant hearing loss. This registration does not test a therapy or establish clinical efficacy.
Show evidence (1 reference)
"The study will allow to identify the prevalence of the SLC17A8 gene mutations in patients suffering from deafness."
Registry summary describes an observational research aim, not a reported prevalence or treatment result.
🐁

Animal Models

2
Slc17a8 null mouse
Homozygous Slc17a8 null mice model complete loss of vesicular glutamate transmission with profound hearing loss and extra-cochlear effects including seizures. The published vestibular study found strongly reduced quantal transmission but relatively preserved spontaneous vestibular nerve activity and most balance tests, with some assay differences. Nonquantal compensation is proposed; this is not proof of normal human vestibular function.
Species
Mouse
Genotype
Slc17a8 (Vglut3) exon 2 targeted deletion, homozygous null
Publication
Show evidence (1 reference)
DOI:10.1038/s41598-026-43836-7 SUPPORT INDIRECT PRIMARY RESULT Model organism
"We propose that non-quantal transmission is sufficient to support vestibular nerve physiology and behavioral function in Vglut3 −/− mice."
The published study proposes a compensatory explanation from mouse physiology and behavioral tests; some assay differences and limited sampling preclude universal normality.
VGLUT3 A224V knock-in mouse
The allele-matched model, and the reason this entry carries two hypothesis groups. A single point mutation was introduced into exon 5 of mouse Slc17a8, exchanging the codon for the alanine that corresponds to human A211. It reproduces the progressive course the null mouse does not, and it reaches a different conclusion about where the disease starts.
Species
Mouse
Genotype
Slc17a8 p.A224V knock-in (mouse equivalent of human p.A211V), homozygous
Publication
{ }

Source YAML

click to show
name: Autosomal Dominant Nonsyndromic Hearing Loss 25
creation_date: "2026-09-01T20:30:00Z"
category: Mendelian
disease_term:
  preferred_term: autosomal dominant nonsyndromic hearing loss 25
  term:
    id: MONDO:0011568
    label: autosomal dominant nonsyndromic hearing loss 25
synonyms:
- DFNA25
- deafness, autosomal dominant 25
- autosomal dominant nonsyndromic deafness 25
- SLC17A8 autosomal dominant nonsyndromic deafness
- autosomal dominant nonsyndromic deafness caused by mutation in SLC17A8
description: >-
  SLC17A8-related autosomal dominant nonsyndromic hearing loss is usually progressive and predominantly
  high-frequency, with variable onset and age-dependent penetrance. VGLUT3 loads glutamate into inner
  hair cell synaptic vesicles. Human segregation establishes the gene-disease relationship, but the dominant
  molecular mechanism remains unresolved. Homozygous null mice lack sound-evoked afferent signaling; homozygous
  A224V knock-in mice, modeling human A211V, develop inner hair cell bundle disruption followed by ribbon
  and exocytosis changes. Heterozygous knock-in mice have a much milder phenotype. These models establish
  complementary experimental findings rather than interchangeable accounts of human disease. The limited
  human otoacoustic-emission data do not settle whether DFNA25 belongs within the auditory neuropathy
  spectrum.
parents:
- Autosomal Dominant Nonsyndromic Hearing Loss
- Hereditary Hearing Loss

external_assertions:
- name: ClinGen SLC17A8-nonsyndromic hearing loss gene-disease validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
  description: >-
    The ClinGen Hearing Loss Gene Curation Expert Panel raised the SLC17A8-autosomal dominant nonsyndromic
    hearing loss relationship from Strong in 2018 to Definitive in June 2023. Its assessment included
    at least eight variants in nine probands and segregation in 28 additional relatives. These are counts
    in that dated evidence assessment, not worldwide case totals or prevalence estimates.
  evidence:
  - reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
    reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC17A8 | HGNC:20151 | nonsyndromic genetic hearing loss | MONDO:0019497 | AD | Definitive"
    explanation: >-
      The expert-panel classification row itself, with gene, disease, inheritance mode and
      verdict.
  - reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
    reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      At least 8 unique variants (missense, frameshift, splice site) have been reported in
      humans in 9 probands
    explanation: >-
      Counts in the June 2023 ClinGen assessment, not current worldwide totals or a prevalence denominator.
  - reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
    reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      As a result of this reevaluation, the classification increased from Strong to
      Definitive due to additional case level evidence
    explanation: >-
      The expert panel upgraded the relationship from Strong to Definitive in 2023.

mechanistic_hypotheses:
- hypothesis_group_id: presynaptic_glutamate_loading_failure
  hypothesis_label: Presynaptic vesicular glutamate loading failure
  status: CANONICAL
  description: >-
    VGLUT3 deficiency prevents vesicular glutamate loading and auditory afferent activation in homozygous
    null mice despite preserved vesicle fusion and cochlear amplification. This is an established null-model
    mechanism and a candidate contributor to human SLC17A8 disease. It does not establish haploinsufficiency
    or uniform transport loss for dominant variants: A211V retains transport in tested heterologous systems,
    and human onset and severity vary.
- hypothesis_group_id: a211v_mechanotransduction_first
  hypothesis_label: Stereociliary mechanotransduction failure preceding synaptic change
  status: EMERGING
  description: >-
    Homozygous A224V mice develop inner hair cell stereocilia disruption and reduced summating potentials
    before marked ribbon enlargement and increased sustained exocytosis. This supports a mechanotransduction-first
    hypothesis in that model. Temporal order does not establish that the bundle lesion causes the synaptic
    changes, and the dominant human mechanism remains unconfirmed.

pathophysiology:
- name: Heterozygous SLC17A8 Variant
  role: trigger
  biological_scale: MOLECULAR
  description: >-
    The founding c.632C>T (p.A211V) variant segregated in two families with evidence of distant shared
    ancestry and was absent from 267 controls. Later reports include c.616dupA (p.M206Nfs*4) and c.763+1G>T.
    The 2016 frameshift report sequenced one proband from an affected pedigree; it did not demonstrate
    segregation across all eight affected relatives. Predicted truncation and splice disruption do not
    establish a shared dominant mechanism.
  genetic_context:
    gene:
      preferred_term: SLC17A8
      term:
        id: hgnc:20151
        label: SLC17A8
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    description: >-
      Reported disease-associated alleles are heterozygous. The entry does not assign one functional-impact
      category across missense, frameshift and splice variants: human dominance and normal heterozygous-null
      mouse hearing do not by themselves distinguish dosage loss, dominant-negative effects or other mechanisms.
  downstream:
  - target: Altered VGLUT3 Function in the Inner Hair Cell
    causal_link_type: DIRECT
    description: >-
      Every proposed mechanism for this disease runs through the transporter that the
      variant sits in.
  evidence:
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two unrelated families, a heterozygous missense mutation, c.632C-->T (p.A211V), was
      found to segregate with DFNA25 deafness and was not present in 267 controls.
    explanation: >-
      The founding allele, its zygosity, its segregation and its control screening.
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The A211 residue is conserved in VGLUT3 across species and in all human VGLUT subtypes
      (VGLUT1-3), suggesting an important functional role.
    explanation: >-
      The conservation argument the founding paper rests the missense call on.
  - reference: PMID:26797701
    reference_title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The novel frameshift mutation, p.M206Nfs*4, in which methionine is changed to
      asparagine at amino acid position 206, resulted in a termination codon at amino acid
      position 209.
    explanation: >-
      The 2016 report identified a frameshift in one sequenced proband and predicted truncation; it did
      not show cosegregation in all affected relatives.
  - reference: PMID:28647561
    reference_title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A novel splicing mutation, c.763+1G>T, in the solute carrier family 17, member 8
      (SLC17A8) gene was identified in the patients, and the genotypes of the mutation were
      co-segregated with the phenotype of HL.
    explanation: >-
      The splice-donor allele and its co-segregation in a three-generation dominant family.

- name: Altered VGLUT3 Function in the Inner Hair Cell
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    VGLUT3 supports glutamate loading into inner hair cell synaptic vesicles. Null mice lack functional
    auditory afferent transmission, but human A211V does not abolish uptake or quantal signaling in tested
    heterologous/autaptic preparations. Central-terminal protein reduction in the knock-in cannot be assumed
    in cochlear cells: the 2021 study found comparable inner hair cell VGLUT3 immunofluorescence and distribution
    between genotypes. Variant-specific effects therefore remain important.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  molecular_functions:
  - preferred_term: vesicular L-glutamate transport by VGLUT3
    term:
      id: GO:0005313
      label: L-glutamate transmembrane transporter activity
  biological_processes:
  - preferred_term: glutamate loading into inner hair cell synaptic vesicles
    term:
      id: GO:0098700
      label: neurotransmitter loading into synaptic vesicle
  cellular_components:
  - preferred_term: inner hair cell synaptic vesicle
    term:
      id: GO:0008021
      label: synaptic vesicle
  downstream:
  - target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
    causal_link_type: DIRECT
    hypothesis_groups:
    - presynaptic_glutamate_loading_failure
    description: >-
      The direct consequence of an unfilled vesicle, and the route the null mouse takes.
  - target: Inner Hair Cell Stereocilia Bundle Disruption
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - a211v_mechanotransduction_first
    description: >-
      The route the allele-matched knock-in mouse takes. It is marked INDIRECT because no
      mechanism connecting an altered vesicular transporter to hair-bundle architecture has
      been demonstrated; the knock-in shows the bundles collapse, not why.
  - target: Synaptic Ribbon Enlargement
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - a211v_mechanotransduction_first
    description: >-
      The A224V genotype is associated with this later synaptic alteration; the intermediates and relationship
      to the early bundle defect remain unresolved.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In addition, IHC ribbon synapses underwent structural and functional modifications at later stages.
      explanation: >-
        The genotype-associated synaptic findings do not prove that reduced receptor potential caused
        them.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: Increased Sustained Inner Hair Cell Exocytosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - a211v_mechanotransduction_first
    description: >-
      The A224V genotype is associated with this later synaptic alteration; the intermediates and relationship
      to the early bundle defect remain unresolved.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained
        releasable pool exocytosis
      explanation: >-
        The genotype-associated synaptic findings do not prove that reduced receptor potential caused
        them.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  evidence:
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In the cochlea, VGLUT3 accumulates glutamate in the synaptic vesicles of the sensory
      inner hair cells (IHCs) before releasing it onto receptors of auditory-nerve terminals.
    explanation: >-
      The normal function of the protein, which is what the disease removes or alters.
  - reference: PMID:26797701
    reference_title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      among its isoforms (VGLUT1-3), only VGLUT3 is expressed selectively in the inner hair
      cells (IHCs)
    explanation: >-
      Inner hair cell expression provides a basis for nonredundant cochlear function. It does not explain
      the absence of extra-auditory findings in every carrier.
    quote_role: BACKGROUND
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This variation does not impair the glutamate vesicular accumulation, neither the
      quantal release nor the quantal content in hippocampal autaptic neurons
    explanation: >-
      A negative result at the level of transport itself, which is why this entry does not
      assert that the human missense allele simply stops glutamate loading. Graded IN_VITRO
      because the measurement is in cultured autaptic neurons.

    quote_role: BACKGROUND
    directness: INDIRECT
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      the p.A224V variant does not disturb the VGLUT3 targeting within the hair cell cytoplasm.
    explanation: >-
      Semi-quantitative mouse cochlear immunofluorescence; this limits extrapolation from reduced central-terminal
      expression.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
  biological_scale: CELLULAR
  description: >-
    In the Ruel Slc17a8-null line, calcium-triggered vesicle turnover was preserved at two weeks and surviving
    ribbons had a normal ultrastructural appearance at three months, while auditory afferent signaling
    failed. Other null-model studies reported thin or elongated ribbons. The findings differ by study
    and preparation; they do not establish universally normal ribbon morphology or uniform transport loss
    in dominant human variants.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  biological_processes:
  - preferred_term: glutamate secretion at the inner hair cell afferent synapse
    modifier: DECREASED
    term:
      id: GO:0014047
      label: glutamate secretion
  downstream:
  - target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
    causal_link_type: DIRECT
    hypothesis_groups:
    - presynaptic_glutamate_loading_failure
    description: >-
      An afferent terminal that receives no transmitter does not fire, however well the
      cochlea in front of it is working.
  evidence:
  - reference: PMID:18215623
    reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We now report that mice lacking VGLUT3 are profoundly deaf due to the absence of
      glutamate release from hair cells at the first synapse in the auditory pathway.
    explanation: >-
      The release failure stated directly, and its location at the first auditory synapse.
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Ca(2+)-triggered synaptic-vesicle turnover was normal in IHCs of Slc17a8 null mice when
      probed by membrane capacitance measurements at 2 weeks of age.
    explanation: >-
      The deliberate negative result that localises the defect to vesicle content rather than
      to exocytosis. Without it the node would be indistinguishable from a fusion defect.
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We conclude that deafness in Slc17a8-deficient mice is due to a specific defect of
      vesicular glutamate uptake and release and that VGLUT3 is essential for auditory coding
      at the IHC synapse.
    explanation: >-
      The founding paper's own conclusion about the null animal.

- name: Inner Hair Cell Stereocilia Bundle Disruption
  biological_scale: CELLULAR
  description: >-
    Homozygous A224V mice show progressive inner hair cell bundle fusion and collapse with relative preservation
    of outer hair cell bundles. VGLUT3 is not localized to stereocilia, and the molecular connection is
    unresolved. Protein misfolding/trafficking effects and interaction with the C57BL/6J Cdh23 background
    are hypotheses. Comparable inner hair cell immunofluorescence argues against gross protein accumulation
    but cannot exclude altered turnover or proteostasis.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  biological_processes:
  - preferred_term: inner hair cell stereocilium bundle organization
    modifier: DECREASED
    term:
      id: GO:0060122
      label: inner ear receptor cell stereocilium organization
  downstream:
  - target: Reduced Inner Hair Cell Receptor Potential
    causal_link_type: DIRECT
    hypothesis_groups:
    - a211v_mechanotransduction_first
    description: >-
      Bundle disruption and reduced summating potential support a mechanotransduction defect in the same
      homozygous model; direct mechanotransducer-current impairment was not measured.
  evidence:
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Scanning electron microscopy examinations demonstrated the collapse of stereocilia
      bundles in IHCs, leaving those from outer hair cells unaffected.
    explanation: >-
      The bundle finding and its restriction to inner hair cells.

- name: Reduced Inner Hair Cell Receptor Potential
  biological_scale: CELLULAR
  description: >-
    The summating potential is the gross cochlear correlate of the inner hair cell receptor
    potential, and it is reduced in the knock-in mouse. Because cochlear amplification is
    intact in the same animals, a smaller receptor potential is being generated from a normal
    mechanical input - which is what a transduction defect in the inner hair cell looks like
    from outside.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  biological_processes:
  - preferred_term: mechanotransduction in the inner hair cell hair bundle
    modifier: DECREASED
    term:
      id: GO:0050910
      label: detection of mechanical stimulus involved in sensory perception of sound
  downstream:
  - target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
    causal_link_type: DIRECT
    hypothesis_groups:
    - a211v_mechanotransduction_first
    description: >-
      Reduced inner hair cell receptor potential is proposed to reduce afferent drive. The model shows
      reduced summating and compound action potentials, but does not directly quantify sound-evoked glutamate
      release.
  evidence:
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The summating potential was reduced, indicating the alteration of inner hair cell (IHC)
      receptor potential.
    explanation: >-
      The measurement and the authors' own interpretation of it.
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These results suggest that DFNA25 stems from a failure in the mechano-transduction
      followed by a change in synaptic transfer.
    explanation: >-
      The ordering claim that this hypothesis group is built on, stated by the authors as a
      suggestion rather than a demonstration - which is why the group is EMERGING.

- name: Synaptic Ribbon Enlargement
  biological_scale: CELLULAR
  description: >-
    Homozygous A224V inner hair cell ribbons enlarge markedly at four to six months, with preserved ribbon
    and synapse counts in the sampled region. This structural change follows early bundle abnormalities.
    Its causal contribution to hearing loss, including whether it is compensatory, remains unresolved.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  evidence:
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, synaptic ribbons became abnormally elongated in knock‐in mice
    explanation: >-
      Mouse cochlear imaging supports ribbon enlargement, not a measured increase in glutamate secretion.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Increased Sustained Inner Hair Cell Exocytosis
  biological_scale: CELLULAR
  description: >-
    At six months, freshly dissected homozygous A224V inner hair cells show increased sustained exocytic
    capacitance responses to long depolarizations, with preserved calcium currents and readily releasable
    pool responses. Capacitance measures membrane fusion rather than vesicular glutamate content or afferent
    neurotransmission. The change may reflect compensation or extrasynaptic release; it is not established
    as a cause of hearing loss.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  evidence:
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained releasable
      pool exocytosis
    explanation: >-
      Ex-vivo patch-clamp measurements in isolated mouse organs of Corti; membrane fusion does not determine
      glutamate quantal content.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
  biological_scale: TISSUE
  description: >-
    Slc17a8-null mice lack sound-evoked auditory responses while retaining otoacoustic emissions and electrically
    evoked brainstem responses. Homozygous A224V mice show progressive auditory threshold elevation with
    preserved emissions. Human otoacoustic-emission data are sparse and differ from these model findings;
    this node records experimental physiology rather than a universal human diagnostic signature.
  cell_types:
  - preferred_term: type 1 spiral ganglion neuron
    term:
      id: CL:4023115
      label: type 1 spiral ganglion neuron
  - preferred_term: cochlear outer hair cell
    term:
      id: CL:0000601
      label: cochlear outer hair cell
  biological_processes:
  - preferred_term: sensory perception of sound
    modifier: DECREASED
    term:
      id: GO:0007605
      label: sensory perception of sound
  locations:
  - preferred_term: organ of Corti
    term:
      id: UBERON:0002227
      label: spiral organ of cochlea
  downstream:
  - target: Secondary Deafferentation of the Inner Hair Cell
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Loss of afferent signaling and later deafferentation occur in null mice; glutamate also has developmental
      effects, so this is not established as a direct use-dependent degeneration mechanism in humans.
  - target: Progressive High-Frequency Sensorineural Hearing Loss
    causal_link_type: DIRECT
    description: >-
      Impaired afferent sound encoding provides a model-based explanation for hearing loss. The progressive
      human course is not reproduced by the congenitally deaf null model.
  evidence:
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses to
      acoustic stimuli, although auditory brainstem responses could be elicited by electrical
      stimuli, and robust otoacoustic emissions were recorded.
    explanation: >-
      All three halves of the dissociation in one sentence: no acoustic neural response,
      preserved electrical response, preserved emissions.
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Using auditory brainstem response and distortion product otoacoustic emissions, we
      showed progressive hearing loss with intact cochlear amplification in the
      VGLUT3A224V/A224V mouse.
    explanation: >-
      The same dissociation in the allele-matched model, and in progressive rather than
      congenital form.
- name: Secondary Deafferentation of the Inner Hair Cell
  biological_scale: TISSUE
  description: >-
    Null mice show loss of afferent synapses, spiral ganglion neurons and lateral efferent endings; some
    neuronal loss precedes hearing onset. Older null cochleae also show inner hair cell and stereocilia
    degeneration. These observations raise questions about treatment timing, but do not define a human
    therapeutic window. Rescue studies in post-neonatal null mice remain distinct from dominant human
    disease.
  cell_types:
  - preferred_term: spiral ganglion neuron
    term:
      id: CL:0011113
      label: spiral ganglion neuron
  downstream:
  - target: Progressive High-Frequency Sensorineural Hearing Loss
    causal_link_type: DIRECT
    description: >-
      Reduced afferent innervation may contribute to sustained hearing impairment in null models; its
      contribution and reversibility in human DFNA25 are unknown.
  evidence:
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Later, the number of afferent synapses, spiral ganglion neurons, and lateral efferent
      endings below sensory IHCs declined.
    explanation: >-
      The deafferentation itself, and its late timing relative to the functional deficit.
  - reference: PMID:18215623
    reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The early degeneration of some cochlear ganglion neurons in knockout mice also
      indicates an important developmental role for the glutamate released by hair cells
      before the onset of hearing.
    explanation: >-
      The developmental component, which is a different claim from use-dependent loss and is
      the reason a congenital null and an adult-onset human disease may diverge here.
  - reference: PMID:40841774
    reference_title: Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In this study, we analyzed the cochlear structure of aged Vglut3KO mice, revealing
      significant degeneration of inner hair cells, synapses, and stereocilia.
    explanation: >-
      The structural endpoint in the aged null animal.

phenotypes:
- category: Otologic
  name: Progressive High-Frequency Sensorineural Hearing Loss
  description: >-
    Progressive, predominantly high-frequency sensorineural hearing loss is the characteristic presentation
    in the founding families. Audiogram shape and severity vary. Family-based ascertainment and a dated
    ClinGen proband count do not support a population-wide phenotype frequency.
  phenotype_term:
    preferred_term: High-frequency sensorineural hearing impairment
    term:
      id: HP:0001757
      label: High-frequency sensorineural hearing impairment
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:11115382
    reference_title: "DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we identified a novel dominant locus, DFNA25, for delayed-onset, progressive,
      high-frequency, nonsyndromic sensorineural hearing loss in a large, multigenerational
      United States family of Czech descent.
    explanation: >-
      The phenotype as defined at the locus, in the founding kindred.
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have identified SLC17A8, which encodes the vesicular glutamate transporter-3
      (VGLUT3), as the gene responsible for DFNA25, an autosomal-dominant form of
      progressive, high-frequency nonsyndromic deafness.
    explanation: >-
      The same phenotype restated once the gene was in hand.

- category: Otologic
  name: Postlingual Delayed Onset
  description: >-
    Postlingual onset is typical, not universal. The 2003 full clinical report includes a child whose
    loss was suspected at birth and confirmed by diagnostic ABR at three months. A normal newborn screen
    cannot exclude later-onset genetic hearing loss.
  phenotype_term:
    preferred_term: Postlingual sensorineural hearing impairment
    term:
      id: HP:0008596
      label: Postlingual sensorineural hearing impairment
  evidence:
  - reference: PMID:12925340
    reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Affected individuals typically manifest a high-frequency, slowly progressive
      sensorineural hearing loss in the postlingual period.
    explanation: >-
      The abstract explicitly says typically. The primary full text documents an early-onset exception;
      normal hearing through speech acquisition is not universal.

  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In general, autosomal dominant nonsyndromic hearing loss is postlingual, progressive, and high frequency.
    explanation: >-
      General clinical baseline, not a SLC17A8-specific age distribution or exclusion of congenital presentations.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
- category: Otologic
  name: Absent Otoacoustic Emissions
  description: >-
    The 2003 family report documents absent transient-evoked emissions and no repeatable ABR in the proband
    III:14. The later knock-in discussion generalizes this to patients, but the primary detailed test
    report is not a cohort-wide denominator. No frequency or universal exclusion of auditory neuropathy
    is inferred. Acquired cochlear injury and mixed mechanisms remain possible explanations.
  phenotype_term:
    preferred_term: Absent otoacoustic emissions
    term:
      id: HP:6000182
      label: Absent otoacoustic emissions
  evidence:
  - reference: PMID:34783032
    reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In contrast, otoacoustic emissions were absent in patients harbouring the p.A211V allele
    explanation: >-
      Secondary discussion of the 2003 human study. Inspection of that primary full text limits the detailed
      OAE/ABR observation to the proband; the plural wording is not evidence for prevalence or a universal
      classification.
    quote_role: BACKGROUND
    directness: INDIRECT
- category: Otologic
  name: Absence of Syndromic Features
  description: >-
    The reported Korean splice-variant family had hearing loss without accompanying symptoms. This supports
    a nonsyndromic human presentation. Vestibular sparing in null mice is a separate experimental observation
    and cannot establish normal vestibular function in every human carrier.
  evidence:
  - reference: PMID:28647561
    reference_title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the clinical information about this family revealed that there are no other symptoms
      accompanied with HL
    explanation: >-
      The nonsyndromic statement in a reported dominant family.
genetic:
- name: SLC17A8
  gene_term:
    preferred_term: SLC17A8
    term:
      id: hgnc:20151
      label: SLC17A8
  relationship_type: CAUSATIVE
  notes: >-
    SLC17A8 encodes VGLUT3. ClinGen classified its dominant nonsyndromic hearing loss relationship as
    Definitive in 2023; the counted probands and variants describe that assessment. A211V, c.616dupA and
    c.763+1G>T differ in their supporting segregation and functional evidence. The 2016 frameshift was
    found in one sequenced proband with an affected pedigree; the splice report demonstrated cosegregation,
    but did not establish transcript consequences in its abstract. The 2021 cell study tested the already
    reported c.616dupA alongside c.824C>A, rather than discovering two additional alleles.
  evidence:
  - reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
    reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Variants in this gene segregated with disease in 28 additional members in two families
    explanation: >-
      The segregation evidence behind the Definitive classification.
  - reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
    reference_title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In summary, SCL17A8 is definitively associated with autosomal dominant nonsyndromic
      hearing loss.
    explanation: >-
      The panel's summary sentence. The gene symbol is transposed in the source record and is
      quoted as written.

inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Autosomal dominant transmission with age-dependent penetrance. Each child of a heterozygous affected
    individual has a 50% chance of inheriting the variant; this is not a 50% probability of hearing loss
    at a specified age. Earlier reported onset in males and a maternal-versus-paternal haplotype pattern
    arose in one pre-gene-mapping kindred and remain unreplicated modifier hypotheses. Normal hearing
    at one assessment does not exclude carrier status. Four tested mitochondrial variants were absent,
    which does not exclude all mitochondrial effects.
  evidence:
  - reference: PMID:12925340
    reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mode of inheritance is autosomal dominant with age-dependent penetrance.
    explanation: >-
      Inheritance mode and the penetrance qualifier together.

  - reference: PMID:12925340
    reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In those inheriting the DFNA25-associated haplotype from an affected mother, hearing
      loss invariably developed by the second decade of life, whereas those inheriting the
      DFNA25 haplotype from an affected father often maintained hearing levels comparable to
      those of age-matched control subjects, even into the seventh decade of life.
    explanation: >-
      The parent-of-origin observation, quoted in full so the size and source of the claim
      travel with it.
  - reference: PMID:12925340
    reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      None of 4 deafness-associated mitochondrial mutations screened (1555A>G, 7445A>G,
      Cins7472, and 7511T>C) were found to segregate in the family.
    explanation: >-
      Only the four tested mitochondrial variants were excluded; the study did not sequence the mitochondrial
      genome or establish the cause of the parent-of-origin pattern.

  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic
      variant to each child.
    explanation: >-
      General autosomal dominant transmission probability, distinct from penetrance.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
animal_models:
- name: Slc17a8 null mouse
  species: Mouse
  genotype: Slc17a8 (Vglut3) exon 2 targeted deletion, homozygous null
  publication: PMID:18674745
  description: >-
    Homozygous Slc17a8 null mice model complete loss of vesicular glutamate transmission with profound
    hearing loss and extra-cochlear effects including seizures. The published vestibular study found strongly
    reduced quantal transmission but relatively preserved spontaneous vestibular nerve activity and most
    balance tests, with some assay differences. Nonquantal compensation is proposed; this is not proof
    of normal human vestibular function.
  modeled_mechanisms:
  - target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The release failure and its localisation to vesicle content rather than fusion, both
      measured directly in the correct cell type.
    limitations: >-
      Homozygous null mice model complete VGLUT3 loss, not the heterozygous human genotypes. Congenital
      profound deafness and mouse epilepsy do not reproduce the typical progressive nonsyndromic presentation.
    readouts:
    - name: Calcium-triggered synaptic vesicle turnover in inner hair cells
      target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
      direction: UNCHANGED
      interpretation: >-
        Exocytosis itself is normal. A deliberate negative result, and the one that makes the
        defect a cargo defect rather than a release-machinery defect.
      evidence:
      - reference: PMID:18674745
        reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Ca(2+)-triggered synaptic-vesicle turnover was normal in IHCs of Slc17a8 null mice
          when probed by membrane capacitance measurements at 2 weeks of age.
        explanation: >-
          The capacitance measurement behind this readout.
    - name: Ribbon synapse ultrastructure at three months
      target: Impaired Glutamate Release at the Inner Hair Cell Ribbon Synapse
      direction: UNCHANGED
      interpretation: >-
        Surviving ribbons appeared normal in this line at three months despite reduced synapse numbers.
        Other null-model studies reported altered ribbon shape; this result is specific to this study.
      evidence:
      - reference: PMID:18674745
        reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Ribbon synapses remaining by 3 months of age had a normal ultrastructural
          appearance.
        explanation: >-
          The electron-microscopy observation behind this readout.
    evidence:
    - reference: PMID:18215623
      reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We now report that mice lacking VGLUT3 are profoundly deaf due to the absence of
        glutamate release from hair cells at the first synapse in the auditory pathway.
      explanation: >-
        Supports treating this model as informative for the release node.
  - target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The three-way dissociation - no acoustic neural response, intact emissions, intact
      electrically evoked brainstem response - measured in one animal.
    limitations: >-
      Detailed human OAE/ABR testing in the 2003 report concerns one proband. The mouse dissociation cannot
      establish the physiology of all carriers or clinical implant outcomes.
    readouts:
    - name: Otoacoustic emissions
      target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
      direction: UNCHANGED
      interpretation: >-
        Outer hair cell amplification is preserved, placing the lesion downstream of the
        cochlear amplifier. A negative result, and the load-bearing one.
      evidence:
      - reference: PMID:18674745
        reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          robust otoacoustic emissions were recorded
        explanation: >-
          The emissions measurement behind this readout.
    - name: Electrically evoked auditory brainstem response
      target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
      direction: UNCHANGED
      interpretation: >-
        The ascending auditory pathway can still be driven when the defective synapse is
        bypassed, which is the observation that makes cochlear implantation biologically
        plausible in this disease.
      evidence:
      - reference: PMID:18674745
        reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          although auditory brainstem responses could be elicited by electrical stimuli
        explanation: >-
          The electrical-stimulation measurement behind this readout.
    evidence:
    - reference: PMID:18674745
      reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses
        to acoustic stimuli, although auditory brainstem responses could be elicited by
        electrical stimuli, and robust otoacoustic emissions were recorded.
      explanation: >-
        Supports treating this model as informative for the dissociation node.
  - target: Secondary Deafferentation of the Inner Hair Cell
    relationship: RECAPITULATES
    fidelity: LOW
    description: >-
      The afferent synapses, spiral ganglion neurons and lateral efferent endings decline
      after the functional deficit is established.
    limitations: >-
      The null model has complete congenital loss of signaling and developmental neuronal effects. Human
      onset is variable and usually later; human synapse-count evidence is lacking in the reviewed sources.
    readouts:
    - name: Afferent synapse and spiral ganglion neuron counts
      target: Secondary Deafferentation of the Inner Hair Cell
      direction: DECREASED
      interpretation: >-
        The afferent population beneath the inner hair cell falls over time in the null
        animal.
      evidence:
      - reference: PMID:18674745
        reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Later, the number of afferent synapses, spiral ganglion neurons, and lateral
          efferent endings below sensory IHCs declined.
        explanation: >-
          The counting result behind this readout.
    evidence:
    - reference: PMID:18215623
      reference_title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The early degeneration of some cochlear ganglion neurons in knockout mice also
        indicates an important developmental role for the glutamate released by hair cells
        before the onset of hearing.
      explanation: >-
        Supports the model for this node while naming the developmental confound that limits
        its fidelity.

  evidence:
  - reference: DOI:10.1038/s41598-026-43836-7
    reference_title: Persistence of vestibular function in the absence of glutamatergic transmission from hair cells
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We propose that non-quantal transmission is sufficient to support vestibular nerve physiology and
      behavioral function in Vglut3 −/− mice.
    explanation: >-
      The published study proposes a compensatory explanation from mouse physiology and behavioral tests;
      some assay differences and limited sampling preclude universal normality.
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
- name: VGLUT3 A224V knock-in mouse
  species: Mouse
  genotype: Slc17a8 p.A224V knock-in (mouse equivalent of human p.A211V), homozygous
  publication: PMID:34783032
  description: >-
    The allele-matched model, and the reason this entry carries two hypothesis groups. A
    single point mutation was introduced into exon 5 of mouse Slc17a8, exchanging the codon
    for the alanine that corresponds to human A211. It reproduces the progressive course the
    null mouse does not, and it reaches a different conclusion about where the disease starts.
  modeled_mechanisms:
  - target: Inner Hair Cell Stereocilia Bundle Disruption
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Collapse and fusion of the inner hair cell stereocilia bundles, with outer hair cell
      bundles spared - the model's primary structural finding.
    limitations: >-
      Homozygosity differs from human dominant inheritance. The C57BL/6J Cdh23 background may modify the
      bundle phenotype; this has not been separated experimentally. No corresponding human cochlear morphology
      was demonstrated.
    readouts:
    - name: Inner hair cell stereocilia bundle morphology by scanning electron microscopy
      target: Inner Hair Cell Stereocilia Bundle Disruption
      direction: ALTERED
      interpretation: >-
        Inner hair cell bundles collapse; outer hair cell bundles do not. The contrast within
        the same cochlea is what makes this a cell-type-specific lesion rather than general
        degeneration.
      evidence:
      - reference: PMID:34783032
        reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Scanning electron microscopy examinations demonstrated the collapse of stereocilia
          bundles in IHCs, leaving those from outer hair cells unaffected.
        explanation: >-
          The microscopy result behind this readout.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        These results suggest that DFNA25 stems from a failure in the mechano-transduction
        followed by a change in synaptic transfer.
      explanation: >-
        The authors' claim that this model's structural finding is the disease's starting
        point, which is what makes the model informative for this node.
  - target: Reduced Inner Hair Cell Receptor Potential
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The functional counterpart of the bundle collapse, measured as a reduced summating
      potential in an animal whose cochlear amplifier is intact.
    limitations: >-
      The summating potential is a gross cochlear potential and an indirect index of the
      inner hair cell receptor potential rather than a recording from the cell. It is not
      measured clinically in DFNA25 patients, so there is no human comparison.
    readouts:
    - name: Summating potential
      target: Reduced Inner Hair Cell Receptor Potential
      direction: DECREASED
      interpretation: >-
        A smaller receptor-potential correlate from a mechanically normal input, consistent
        with a transduction rather than an amplification deficit.
      evidence:
      - reference: PMID:34783032
        reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          The summating potential was reduced, indicating the alteration of inner hair cell
          (IHC) receptor potential.
        explanation: >-
          The measurement behind this readout.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The summating potential was reduced, indicating the alteration of inner hair cell (IHC) receptor
        potential.
      explanation: >-
        Measured cochlear potential supports the model-to-mechanism link, with the indirect nature of
        the receptor-potential readout stated in its limitations.
  - target: Synaptic Ribbon Enlargement
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Ribbon enlargement at four to six months in the homozygous knock-in.
    limitations: >-
      Elongated and enlarged ribbons are not necessarily opposite findings. Morphology differs between
      studies and models; compensation, pathogenic contribution and relevance to human heterozygotes remain
      unresolved.
    readouts:
    - name: Synaptic ribbon size by super-resolution microscopy
      target: Synaptic Ribbon Enlargement
      direction: INCREASED
      interpretation: >-
        Ribbons are larger than wild type in the knock-in animal.
      evidence:
      - reference: PMID:34783032
        reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Using super-resolution microscopy, we observed oversized synaptic ribbons
        explanation: >-
          The imaging result behind this readout.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In addition, IHC ribbon synapses underwent structural and functional modifications at
        later stages.
      explanation: >-
        Supports the model for this node and fixes its position late in the sequence.
  - target: Increased Sustained Inner Hair Cell Exocytosis
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Increased sustained exocytic capacitance response at six months.
    limitations: >-
      An ex-vivo membrane-fusion readout, not a direct measure of glutamate release or evidence that increased
      secretion causes the hearing deficit.
    readouts:
    - name: Sustained releasable pool exocytosis rate
      target: Increased Sustained Inner Hair Cell Exocytosis
      direction: INCREASED
      interpretation: >-
        Sustained vesicle fusion is increased under imposed depolarization; glutamate quantal content
        was not measured.
      evidence:
      - reference: PMID:34783032
        reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          patch-clamp membrane capacitance measurements showed an increase in the rate of the
          sustained releasable pool exocytosis
        explanation: >-
          The capacitance measurement behind this readout.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        patch-clamp membrane capacitance measurements showed an increase in the rate of the sustained
        releasable pool exocytosis
      explanation: >-
        Ex-vivo patch-clamp measurements in isolated mouse organs of Corti; membrane fusion does not determine
        glutamate quantal content.
      quote_role: PRIMARY_RESULT
      directness: DIRECT
  - target: Progressive High-Frequency Sensorineural Hearing Loss
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Progressive hearing loss with intact cochlear amplification, which is the human course
      in outline.
    limitations: >-
      Homozygotes progress, whereas heterozygotes have only mild impairment over the studied interval.
      Human dominant inheritance, audiogram configuration and limited human OAE findings are not fully
      reproduced. Lifespan and background effects remain hypotheses.
    readouts:
    - name: Auditory brainstem response threshold
      target: Progressive High-Frequency Sensorineural Hearing Loss
      direction: INCREASED
      interpretation: >-
        Thresholds rise progressively with age. The direction is INCREASED because the
        readout is a threshold - worse hearing means more sound is required to evoke a
        response.
      evidence:
      - reference: PMID:34783032
        reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Mutant mice carrying the VGLUT3-p.A211V variant show progressive hearing loss.
        explanation: >-
          The progressive threshold shift behind this readout, stated in the paper's key
          points.
    - name: Distortion-product otoacoustic emissions
      target: Progressive High-Frequency Sensorineural Hearing Loss
      direction: UNCHANGED
      interpretation: >-
        Cochlear amplification is intact while brainstem responses deteriorate. A negative
        result that separates this from an outer-hair-cell hearing loss.
      evidence:
      - reference: PMID:34783032
        reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          we showed progressive hearing loss with intact cochlear amplification in the
          VGLUT3A224V/A224V mouse
        explanation: >-
          The emissions measurement behind this readout.
    evidence:
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Our data show that the VGLUT3A224V/A224V mice phenocopy human progressive hearing
        loss.
      explanation: >-
        The authors' own claim that this model matches the human course, which is what
        licenses using it for the clinical phenotype node.
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: >-
        the mouse model harbouring the VGLUT3-p.A224V variant mimics a progressive hearing loss
        with auditory neuropathy features, but might be arguable so far as to consider it as a
        faithful model of DFNA25
      explanation: >-
        The same authors' qualification of the sentence above, in the discussion rather than the
        abstract. It is recorded as REFUTE against the link's claim of fidelity, and it is why
        this relationship is PARTIALLY_RECAPITULATES.
    - reference: PMID:34783032
      reference_title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        However, the mild hearing impairment in the VGLUT3+/A224V heterozygotes contrasts with
        the dominant transmission in DFNA25
      explanation: >-
        The zygosity mismatch measured rather than assumed: the genotype that matches a patient
        is only mildly affected in this animal.

diagnosis:
- name: Pure-Tone Audiometry
  description: >-
    Audiometric assessment documents and tracks the delayed-onset,
    progressive, high-frequency-predominant sensorineural hearing loss that
    defines DFNA25, as a step separate from the molecular testing described
    in the row below.
  diagnosis_term:
    preferred_term: audiometric test
    term:
      id: NCIT:C38036
      label: Audiometric Test
  measurements:
  - preferred_term: pure-tone threshold audiometry
    term:
      id: LOINC:89015-2
      label: Pure tone threshold audiometry panel
  - preferred_term: hearing threshold, left ear, 500 Hz
    term:
      id: LOINC:89024-4
      label: Hearing threshold Ear - left --500 Hz
  - preferred_term: hearing threshold, right ear, 500 Hz
    term:
      id: LOINC:89025-1
      label: Hearing threshold Ear - right --500 Hz
  - preferred_term: hearing threshold, left ear, 1000 Hz
    term:
      id: LOINC:89016-0
      label: Hearing threshold Ear - left --1000 Hz
  - preferred_term: hearing threshold, right ear, 1000 Hz
    term:
      id: LOINC:89017-8
      label: Hearing threshold Ear - right --1000 Hz
  - preferred_term: hearing threshold, left ear, 2000 Hz
    term:
      id: LOINC:89018-6
      label: Hearing threshold Ear - left --2000 Hz
  - preferred_term: hearing threshold, right ear, 2000 Hz
    term:
      id: LOINC:89019-4
      label: Hearing threshold Ear - right --2000 Hz
  - preferred_term: hearing threshold, left ear, 4000 Hz
    term:
      id: LOINC:89022-8
      label: Hearing threshold Ear - left --4000 Hz
  - preferred_term: hearing threshold, right ear, 4000 Hz
    term:
      id: LOINC:89023-6
      label: Hearing threshold Ear - right --4000 Hz
  notes: >-
    No reference range is recorded: the cited founding-locus report states
    the loss is progressive and high-frequency-predominant but gives no
    severity grade or dB cut-off specific to DFNA25.
  evidence:
  - reference: PMID:11115382
    reference_title: "DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we identified a novel dominant locus, DFNA25, for delayed-onset, progressive,
      high-frequency, nonsyndromic sensorineural hearing loss in a large, multigenerational
      United States family of Czech descent.
    explanation: >-
      States the progressive, high-frequency-predominant audiometric pattern
      that these measurements document and track over serial audiograms.
- name: Molecular testing of SLC17A8
  description: >-
    Combine audiologic assessment, examination for syndromic findings, family history and molecular testing.
    A hearing-loss multigene panel or genomic testing can identify SLC17A8 alongside overlapping causes.
    Testing a known familial pathogenic variant clarifies carrier status; audiometry independently measures
    current hearing and progression.
  evidence:
  - reference: PMID:28647561
    reference_title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To identify a causative mutation of HL in this family, we performed whole-exome
      sequencing of 4 family members, 3 affected and an unaffected.
    explanation: >-
      Family exome sequencing identified the splice-site variant; the paper does not state that linkage
      was unavailable.
  - reference: PMID:26797701
    reference_title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this study, we performed a genetic analysis of 87 unrelated Korean patients with
      ADNSHL to determine whether the SLC17A8 gene affects hearing ability in the Korean
      population.
    explanation: >-
      The screened cohort comprised 87 unrelated dominant-hearing-loss probands; the single candidate
      frameshift does not provide a general diagnostic yield.

  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Single-gene testing (sequence analysis of a given gene, followed by gene-targeted deletion/duplication
      analysis) is rarely useful and typically NOT recommended.
    explanation: >-
      General initial diagnostic strategy; targeted testing for a known familial variant is a separate
      indication.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
- name: Variant interpretation as a distinct problem in this gene
  description: >-
    Evaluate each variant using segregation, population data, phenotype and functional evidence. A VUS
    does not confirm or exclude DFNA25. The 2016 full text found I78V did not cosegregate and A374S also
    occurred in normal-hearing controls, illustrating why conservation and predictions alone are insufficient.
    Cell-culture effects of c.616dupA and c.824C>A are functional support, not proof of a shared mechanism
    or clinical pathogenicity.
  evidence:
  - reference: PMID:34145196
    reference_title: "The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Although several suspected pathogenic mutations of the SLC17a8 gene have been
      identified in humans, few studies have confirmed their pathogenicity.
    explanation: >-
      The interpretation problem stated by the authors as their motivation.
  - reference: PMID:34145196
    reference_title: "The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The c.616dupA mutation in the SLC17a8 gene resulted in a significant decrease in
      transcriptional activity of mRNA, and the expression of VGluT3 was also reduced. The
      c.824C>A mutation in the SLC17a8 gene resulted in abnormal VGluT3, although this
      mutation did not affect the transcriptional activity of mRNA.
    explanation: >-
      Two alleles in one gene with two different molecular consequences, measured in cell
      culture.

  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The identification of variant(s) of uncertain significance cannot be used to confirm or rule out
      the diagnosis.
    explanation: >-
      General variant-interpretation guidance.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
treatments:
- name: Hearing Aids
  therapeutic_modality: DEVICE
  description: >-
    Offer audiologist-fitted amplification and communication support according to hearing thresholds,
    speech testing and individual preferences. This follows general genetic hearing-loss care; genotype-specific
    benefit cannot be predicted from the null mouse or an isolated OAE finding.
  treatment_term:
    preferred_term: hearing aid fitting
    term:
      id: NCIT:C15315
      label: Rehabilitation
    qualifiers:
    - predicate:
        preferred_term: medical device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: hearing aid
        term:
          id: NCIT:C183182
          label: Hearing Aid

  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      customized by an audiologist to the degree and frequency of hearing loss, can be used in individuals
      with mild-to-severe hearing loss.
    explanation: >-
      General hearing-aid guidance, not a DFNA25 outcome estimate.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
- name: Cochlear Implantation
  therapeutic_modality: DEVICE
  description: >-
    Consider cochlear implantation under standard audiologic candidacy assessment when amplification provides
    insufficient benefit. Preserved electrically evoked responses in null mice provide mechanistic plausibility,
    but do not establish human DFNA25 implant efficacy or guarantee preservation of the neural target.
  treatment_term:
    preferred_term: cochlear device implantation
    term:
      id: NCIT:C15329
      label: Surgical Procedure
    qualifiers:
    - predicate:
        preferred_term: medical device
        term:
          id: NCIT:C16830
          label: Medical Device
      value:
        preferred_term: cochlear implant
        term:
          id: NCIT:C157820
          label: Cochlear Implant
  target_mechanisms:
  - target: Failure of Auditory Nerve Activation with Preserved Cochlear Amplification
    treatment_effect: BYPASSES
    description: >-
      Direct electrical stimulation of the spiral ganglion substitutes for the defective
      inner hair cell synapse.
    evidence:
    - reference: PMID:18674745
      reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        although auditory brainstem responses could be elicited by electrical stimuli
      explanation: >-
        The preserved electrical responsiveness that an implant would exploit. Model evidence
        for a human intervention, so the claim in the description is plausibility rather than
        efficacy.

  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Habilitation for hearing loss includes improved access to sound through hearing aids or cochlear
      implants
    explanation: >-
      General habilitation options; no SLC17A8-specific outcome is asserted.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
- name: AAV-mediated VGLUT3 Gene Replacement
  therapeutic_modality: GENE_THERAPY
  description: >-
    Preclinical gene replacement has restored auditory responses in homozygous null mice after neonatal
    cochlear AAV1 delivery, adult intracisternal delivery through the cochlear aqueduct, and AAV8 injection
    at five weeks with assessment 27 weeks later. The latter does not demonstrate reversal after treatment
    of already aged animals. These interventions have not established efficacy in dominant A211V disease;
    augmentation, suppression or combined strategies require variant-specific testing. No human SLC17A8
    interventional study was identified in the reviewed research; the registered NCT01802190 study is
    observational.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Altered VGLUT3 Function in the Inner Hair Cell
    treatment_effect: RESTORES
    description: >-
      Restoring VGLUT3 protein to the inner hair cell addresses the molecular lesion rather
      than its consequences - in an animal that has none of the protein to begin with.
    evidence:
    - reference: PMID:22841313
      reference_title: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Within 2 weeks of AAV1-VGLUT3 delivery, auditory brainstem response (ABR) thresholds
        normalize, along with partial rescue of the startle response.
      explanation: >-
        The functional rescue, in the null mouse.
    - reference: PMID:40841774
      reference_title: Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Auditory brainstem response (ABR) testing demonstrated restoration of auditory
        function following gene therapy.
      explanation: >-
        Mice were injected at five weeks and evaluated 27 weeks later, so the aged endpoint does not establish
        efficacy when treatment starts in aged animals.
  evidence:
  - reference: PMID:22841313
    reference_title: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These findings represent a successful restoration of hearing by gene replacement in
      mice, which is a significant advance toward gene therapy of human deafness.
    explanation: >-
      The authors' own framing of how far the result reaches - toward human therapy, not to
      it.

  - reference: DOI:10.1126/scitranslmed.abq3916
    reference_title: Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      rescued hearing in adult deaf Slc17A8 −/− mice by restoring VGLUT3 protein expression in inner hair
      cells
    explanation: >-
      Primary 2023 adult-null-mouse rescue supporting the CSF-delivery theme in the research report.
    quote_role: PRIMARY_RESULT
    directness: DIRECT
- name: Audiologic surveillance and noise protection
  description: >-
    Follow hearing serially and adjust rehabilitation as needed. Avoid repeated loud-noise overexposure
    using general hearing-loss guidance. No SLC17A8-specific surveillance interval or proven genotype-specific
    noise susceptibility is inferred.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Regular follow up is recommended for all individuals with genetic hearing loss
    explanation: >-
      General surveillance baseline.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      persons with documented hearing loss should be counseled appropriately and repeated overexposure
      to loud noises should be avoided.
    explanation: >-
      General precaution; no demonstrated DFNA25-specific disease-modifying effect.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
- name: Genetic counseling
  description: >-
    Discuss 50% variant transmission per pregnancy, variable onset and penetrance, familial testing and
    reproductive options. Counseling should respect individual communication and reproductive preferences.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Individuals with autosomal dominant hearing loss have a 50% chance of transmitting the pathogenic
      variant to each child.
    explanation: >-
      General autosomal dominant transmission probability, distinct from penetrance.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
    reference_title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Once the pathogenic variant(s) have been identified in the family, prenatal and preimplantation
      genetic testing for genetic hearing loss are possible.
    explanation: >-
      General reproductive-testing guidance after identification of the familial variant.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
differential_diagnoses:
- name: Presbycusis and noise-induced hearing loss
  description: >-
    Age-related and noise-related hearing loss can resemble DFNA25. Pedigree information and molecular
    testing help distinguish causes, while acquired exposures and genetic disease may coexist. Audiogram
    shape alone is insufficient.
  evidence:
  - reference: PMID:12925340
    reference_title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is difficult to differentiate delayed-onset high-frequency sensorineural hearing
      loss inherited as a simple mendelian trait like DFNA25-associated hearing loss from
      that due to noise exposure or presbycusis, disorders that may also have a genetic
      component.
    explanation: >-
      The difficulty stated as the study's own conclusion.
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autosomal-dominant sensorineural hearing loss is genetically heterogeneous, with a
      phenotype closely resembling presbycusis, the most common sensory defect associated
      with aging in humans.
    explanation: >-
      The same resemblance stated for the dominant class DFNA25 belongs to.

    quote_role: BACKGROUND
- name: OTOF-related auditory neuropathy (DFNB9)
  description: >-
    OTOF-related hearing loss is a presynaptic disorder with recessive inheritance, contrasting with dominant
    SLC17A8 disease. Typical clinical patterns can guide testing, but overlapping and atypical presentations
    require molecular interpretation. Null-mouse physiology and sparse human emission data do not reliably
    distinguish every patient.
  evidence:
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Null mice with a targeted deletion of Slc17a8 exon 2 lacked auditory-nerve responses to
      acoustic stimuli, although auditory brainstem responses could be elicited by electrical
      stimuli, and robust otoacoustic emissions were recorded.
    explanation: >-
      The physiological pattern DFNA25's null mouse shares with the OTOF synaptopathies, which
      is what makes DFNB9 the mechanistic differential.

- name: CABP2-related nonsyndromic hearing loss (DFNB93)
  description: >-
    CABP2-related DFNB93 is recessive and involves regulation of presynaptic calcium channels. Preserved
    emissions in a reported CABP2 patient support a synaptopathy in that case; comprehensive emission
    phenotyping remains limited. The isolated absent-emission observation in DFNA25 is insufficient for
    a universal mechanistic contrast.
  evidence:
  - reference: PMID:40927552
    reference_title: "Is CABP2-Associated Hearing Loss (DFNB93) a Gene Therapy Target? Preclinical Progress and Patient Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Otoacoustic emissions have been observed in an Italian family with a homozygous CABP2
      variant, indicating preservation of outer hair cell-mediated cochlear amplification.
    explanation: >-
      A review summarizes a human CABP2 observation; it does not establish uniform emissions across either
      disease.
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
  - reference: PMID:18674745
    reference_title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We have identified SLC17A8, which encodes the vesicular glutamate transporter-3
      (VGLUT3), as the gene responsible for DFNA25, an autosomal-dominant form of
      progressive, high-frequency nonsyndromic deafness.
    explanation: >-
      Dominant inheritance and the characteristic high-frequency pattern help frame the differential;
      the quote does not establish universal postlingual onset.

discussions:
- discussion_id: mismatch_zygosity_of_the_dfna25_mouse_models
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Heterozygous SLC17A8 Variant
  - animal_models#VGLUT3 A224V knock-in mouse
  prompt: >-
    Does either mouse model DFNA25, when both are homozygous and the heterozygote - the
    genotype a patient actually has - is only mildly affected?
  rationale: >-
    Homozygous knock-in mice have progressive impairment but heterozygotes have only mild changes over
    six months. Lifespan, allele dose, genetic background and species-specific biology may contribute.
    Null rescue does not select the optimal strategy for dominant human alleles.
  proposed_experiments:
  - experiment_id: dfna25_aged_heterozygous_knockin
    name: Lifespan-long auditory phenotyping of heterozygous VGLUT3 A224V mice
    description: >-
      Follow heterozygous A224V and wild-type littermates across age with serial ABR, emissions and bundle
      morphology, accounting for background-related hearing loss.
    would_support:
    - pathophysiology#Heterozygous SLC17A8 Variant
    supporting_outcome:
    - A widening deficit would support age-dependent expression in this mouse model, without proving that homozygous pathology transfers to humans.
    refuting_outcome:
    - A plateau would argue against continued progression under the tested conditions; it would not establish universal tolerance of one allele.
- discussion_id: gap_why_patient_emissions_are_absent
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Absent Otoacoustic Emissions
  - mechanistic_hypotheses#presynaptic_glutamate_loading_failure
  prompt: >-
    How representative is the absent-emission finding in the original DFNA25 proband?
  rationale: >-
    The detailed primary human observation concerns one proband, while both main mouse models retain emissions.
    Broader human OAE, cochlear microphonic, ABR, age and exposure data are needed to separate cochlear
    and neural contributions. Controlled mouse noise experiments can test model susceptibility but cannot
    establish the cause of human findings.
  proposed_experiments:
  - experiment_id: dfna25_noise_vulnerability_by_allele_dose
    name: Noise vulnerability in mice carrying one or two VGLUT3-p.A224V alleles
    description: >-
      Expose wild-type, heterozygous and homozygous A224V mice to a controlled acoustic
      overexposure and compare distortion-product emission loss and threshold shift against
      unexposed littermates. This is the experiment the knock-in authors name as necessary to
      determine whether acoustic injury accounts for the discrepancy between mouse and patient
      emissions.
    would_support:
    - phenotypes#Absent Otoacoustic Emissions
    supporting_outcome:
    - Greater emission loss after controlled noise would support genotype-dependent susceptibility in mice and motivate human exposure studies.
    refuting_outcome:
    - No genotype difference would weaken this model-specific noise hypothesis under the tested exposure; it would not resolve human auditory-neuropathy classification.
- discussion_id: gap_where_the_dfna25_lesion_starts
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - mechanistic_hypotheses#presynaptic_glutamate_loading_failure
  - mechanistic_hypotheses#a211v_mechanotransduction_first
  prompt: >-
    How does a vesicular glutamate transporter variant collapse the inner hair cell stereocilia
    bundle?
  rationale: >-
    A224V mice show bundle collapse despite retained transport in heterologous systems and comparable
    cochlear VGLUT3 immunofluorescence. Proteostasis, trafficking and the Cdh23 background remain candidate
    contributors. Identifying the mechanism could guide therapy, but a gene-directed intervention might
    affect both bundle and synaptic consequences.
  proposed_experiments:
  - experiment_id: dfna25_vglut3_localisation_in_knockin_hair_cells
    name: Subcellular localisation and turnover of VGLUT3-p.A224V in inner hair cells
    description: >-
      Track variant VGLUT3 in knock-in inner hair cells by immunogold electron microscopy and
      pulse-chase, testing directly whether it accumulates in the soma or apical compartment,
      whether proteostasis markers are engaged, and whether the cuticular plate cytoskeleton is
      disturbed before the bundles collapse.
    would_support:
    - mechanistic_hypotheses#a211v_mechanotransduction_first
    supporting_outcome:
    - Accumulation and proteostasis changes preceding bundle collapse would support this candidate mechanism; perturbation and rescue would be needed to test causation.
    refuting_outcome:
    - Normal localization and turnover would weaken this mechanism without excluding other allele-dependent or background effects.
- discussion_id: gap_dfna25_allele_class_heterogeneity
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#SLC17A8
  prompt: >-
    Do the truncating and splice SLC17A8 alleles cause the same disease as the missense
    founder allele?
  rationale: >-
    Missense, frameshift and splice alleles have unequal human and functional evidence. The frameshift
    and c.824C>A expression study retested reported alleles. Allelic heterogeneity does not by itself
    justify splitting a disease, and a normal heterozygous-null mouse does not resolve the human dominant
    mechanism.
  proposed_experiments:
  - experiment_id: dfna25_allele_class_audiogram_comparison
    name: Audiometric comparison of missense against truncating SLC17A8 carriers
    description: >-
      Collect audiograms and ages at onset across all published SLC17A8 heterozygotes and
      compare the founder missense families against the frameshift and splice-donor families,
      testing whether onset, progression rate and audiometric shape differ by allele class.
    would_support:
    - genetic#SLC17A8
    supporting_outcome:
    - Overlapping profiles would support shared clinical features without proving a shared molecular mechanism.
    refuting_outcome:
    - Reproducible differences would support allele-specific prognosis and further mechanistic work, without by themselves requiring separate disease entities.
notes: >-
  This is a genetic disease eligible for review despite noise exposure being a possible modifier and differential.
  SLC17A8 and the auditory brainstem response abbreviation ABR were distinguished in the research preflight;
  ABR is not a rival causal gene here. The matching research narrative, table, bibliography and citation
  sidecar were assessed. The report misidentifies PMID:22794260 as the 2012 rescue study; the correct
  PMID:22841313 is retained. Incorrect suggested HPO bindings were not imported. Normal-cell vesicle proteomics
  is background, not a disease biomarker. Adult CSF-mediated null-mouse rescue is now represented with
  the primary 2023 citation.

  The full GeneReviews Genetic Hearing Loss Overview supplies general clinical, diagnostic, management,
  surveillance and counseling context; it is not a DFNA25-specific chapter and does not establish gene-specific
  phenotype frequencies or follow-up intervals. Dated ClinGen counts are not worldwide prevalence. No
  quantitative progression rate is inferred from a single-family serial-audiogram report.

  The 2003 JAMA primary full text was inspected online. Automated cache retrieval returned 403 for HTML
  and PDF, so cached abstract quotations and the explicitly secondary OAE quotation are retained without
  inventing a full-text cache. The full text narrows the OAE/ABR denominator and documents an early-onset
  exception. Absence of emissions alone does not settle the disease classification.

  The PMID:41279968 cache combines a 2025 preprint abstract with the later published PDF. The published
  vestibular study is cited separately by DOI:10.1038/s41598-026-43836-7; its mouse findings are not human
  phenotype evidence. Full-text discussion limits apparently spared balance to the assays tested and proposes,
  rather than proves, nonquantal compensation.

references:
- reference: PMID:18674745
  title: "Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice."
- reference: PMID:12925340
  title: Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
- reference: PMID:11115382
  title: "DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24."
- reference: PMID:34783032
  title: VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
- reference: PMID:18215623
  title: Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
- reference: PMID:22841313
  title: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
- reference: PMID:40841774
  title: Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
- reference: PMID:26797701
  title: Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
- reference: PMID:28647561
  title: Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
- reference: PMID:40927552
  title: "Is CABP2-Associated Hearing Loss (DFNB93) a Gene Therapy Target? Preclinical Progress and Patient Registry."
- reference: PMID:34145196
  title: "The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3."
- reference: CGGV:assertion_8c399400-090a-4b2e-93ff-0c4915ce81c7-2023-06-01T160000.000Z
  title: SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1434/?report=reader
  title: Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
  tags:
  - GeneReviews
- reference: DOI:10.1038/s41598-026-43836-7
  title: Persistence of vestibular function in the absence of glutamatergic transmission from hair cells
- reference: DOI:10.1126/scitranslmed.abq3916
  title: Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice
- reference: clinicaltrials:NCT01802190
  title: Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.
clinical_trials:
- name: NCT01802190
  phase: NOT_APPLICABLE
  description: >-
    Observational genetic screening and phenotypic characterization of SLC17A8/DFNA25 and POU4F3/DFNA15
    in dominant hearing loss. This registration does not test a therapy or establish clinical efficacy.
  evidence:
  - reference: clinicaltrials:NCT01802190
    reference_title: Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The study will allow to identify the prevalence of the SLC17A8 gene mutations in patients suffering
      from deafness.
    explanation: >-
      Registry summary describes an observational research aim, not a reported prevalence or treatment
      result.
  status: TERMINATED
  notes: 'ClinicalTrials.gov API checked 2026-09-23: observational study, actual enrollment 50; record last updated July 2015 and terminated with no convincing results reported as the reason. Registration is not evidence of a measured DFNA25 prevalence.'
📚

References & Deep Research

References

16
Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice.
No top-level findings curated for this source.
Phenotypic characterization of hereditary hearing impairment linked to DFNA25.
No top-level findings curated for this source.
DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24.
No top-level findings curated for this source.
VGLUT3-p.A211V variant fuses stereocilia bundles and elongates synaptic ribbons.
No top-level findings curated for this source.
Sensorineural deafness and seizures in mice lacking vesicular glutamate transporter 3.
No top-level findings curated for this source.
Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy.
No top-level findings curated for this source.
Gene therapy restores auditory function and rescues damaged inner hair cells in an aged Vglut3 knockout mouse model.
No top-level findings curated for this source.
Screening of the SLC17A8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in Koreans.
No top-level findings curated for this source.
Identification of a novel splicing mutation within SLC17A8 in a Korean family with hearing loss by whole-exome sequencing.
No top-level findings curated for this source.
Is CABP2-Associated Hearing Loss (DFNB93) a Gene Therapy Target? Preclinical Progress and Patient Registry.
No top-level findings curated for this source.
The c.824C>A and c.616dupA mutations in the SLC17a8 gene are associated with auditory neuropathy and lead to defective expression of VGluT3.
No top-level findings curated for this source.
SLC17A8 / nonsyndromic genetic hearing loss (Definitive)
No top-level findings curated for this source.
Genetic Hearing Loss Overview - GeneReviews® - NCBI Bookshelf
No top-level findings curated for this source.
Persistence of vestibular function in the absence of glutamatergic transmission from hair cells
No top-level findings curated for this source.
Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice
No top-level findings curated for this source.
Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Autosomal Dominant Nonsyndromic Hearing Loss 25 (DFNA25, SLC17A8/VGLUT3) · 2026-09-02T03:47:22Z · View source

New Disease entry for MONDO:0011568 (DFNA25), curated from primary literature plus a falcon deep-research run (preflight WARN, exit 0; the 'ABR' rival-gene warning is the auditory brainstem response acronym, a false positive). entry_type decision: DISEASE. MONDO:0011568 was bound nowhere in kb/, DFNA25 has its own OMIM phenotype entry, DFNA locus number and a ClinGen Definitive gene-disease assertion, and no existing entry binds SLC17A8, so there was no coverage to duplicate. The stub was deleted. Relationship to the two neighbouring entries, which was the substantive question on the issue. DFNA25 is NOT recorded as a subtype of Auditory_Neuropathy. The defining physiological signature of that class - preserved otoacoustic emissions with an abnormal auditory brainstem response - is demonstrated only in the Slc17a8-null and A224V knock-in mice and has never been measured in a DFNA25 patient. The Auditory_Neuropathy has_subtypes list is populated by entities whose classification rests on a human clinical finding (OTOF, DIAPH3, ATP11A, AIFM1, TMEM43). The contrast with Autosomal_Recessive_Nonsyndromic_Hearing_Loss_93 (CABP2) is recorded explicitly in a differential_diagnoses entry and in notes: DFNB93 has a published human emissions observation and therefore states its synaptopathy classification in its pathophysiology, while DFNA25 states the dissociation for the mouse only and carries the human question as an open KNOWLEDGE_GAP. Two mechanistic_hypotheses groups are curated rather than one, because the two mouse models disagree. The Slc17a8 null (presynaptic_glutamate_loading_failure, CANONICAL) shows empty-vesicle release with normal exocytosis. The allele-matched VGLUT3 A224V knock-in (a211v_mechanotransduction_first, EMERGING) reports inner hair cell stereocilia collapse and a reduced summating potential first, with ribbon changes later, and its authors conclude DFNA25 begins in mechanotransduction. A HUMAN_MODEL_MISMATCH discussion records the genetics problem: heterozygous Slc17a8 knockout mice hear normally while heterozygous human p.A211V carriers go deaf, so neither model matches the patients' genotype and the choice between gene addition and allele-selective knockdown is unresolved. functional_impact_category is deliberately left empty on the trigger node for the same reason. Correction made later in the same session, after the entry was first written. The full text of PMID:34783032 was searched for the heterozygous-mouse phenotype and turned up something more important: otoacoustic emissions are reported ABSENT in p.A211V patients - the opposite of both mouse models - and that paper concludes on that basis that DFNA25 is more likely a progressive hearing loss than an auditory neuropathy. The first draft of this entry asserted that patient emissions had never been measured, which was wrong. The correction strengthens the disposition rather than changing it: DFNA25 stays out of the Auditory_Neuropathy has_subtypes list, now for a positive cited reason rather than for absence of evidence. Added an 'Absent Otoacoustic Emissions' phenotype (HP:6000182) carrying the finding, the authors' classification conclusion, and their untested alternative explanation (lifetime noise exposure) as a NO_EVIDENCE item; added a REFUTE evidence item against the preserved-amplification pathophysiology node; and replaced the lesion-site knowledge gap with two better ones - why patient emissions are absent, and how a vesicular transporter variant collapses a stereocilia bundle it is not present in. The same full-text search also replaced an unsourced prose claim. The first draft said heterozygous Slc17a8 KNOCKOUT mice hear normally, which could not be quoted from any cached reference. The citable fact is better: heterozygous A224V KNOCK-IN mice - the genotype that matches a patient - show only mild impairment, which the authors themselves say contrasts with the dominant transmission in the human families. The HUMAN_MODEL_MISMATCH was rewritten around that and its proposed experiment changed, because the experiment the first draft proposed had already been done. Process note worth recording: the correction took two commits because the first edit script aborted partway on a failed string match and wrote nothing, so two passages - the notes paragraph and the DFNB93 differential - kept the pre-correction wording while the rest of the entry had moved. Grepping the file for the stale phrase is what caught it. After any script-driven edit, confirm the change landed rather than assuming the script ran to completion. Review round (ai4c-reviewer). The first run approved at 45a4e221bc; a re-run of the same check on the same commit returned CHANGES_REQUESTED, so the later verdict was treated as live rather than stale after confirming both reviews carry the head SHA. One blocking item, verified before acting and correct: Cochlear Implantation bound only NCIT:C15329 Surgical Procedure while Hearing Aids in the same file attached the NCIT:C16830 -> NCIT:C183182 device qualifier pair, so the file was inconsistent with itself and NCIT:C157820 was unreachable from the entry. CLAUDE.md names cochlear implantation as the worked case for exactly this pattern and fifteen entries already follow it. Added the qualifier pair; just check-qualifier-terms-online passes (325 labels matched, 97 resolved online). Two suggestions taken. The DFNB93 differential argued a contrast whose DFNB93 half - emissions present - was unsourced in this file; it now cites PMID:40927552 for the Italian family observation, so both halves of the comparison carry evidence. And the notes now close the GeneReviews loop: there is no SLC17A8 or DFNA25 chapter, and the adjacent Genetic Hearing Loss Overview (PMID:20301607) is deliberately not tagged because the cached record does not mention SLC17A8, DFNA25 or VGLUT3 - tagging it would assert a coverage relationship the source does not have. Two suggestions declined with reasons on the PR: noise exposure stays out of environmental: because the entry treats it as an open question in a knowledge gap rather than an asserted exposure, and adding it would assert what the gap exists to ask; and the DR-surfaced supportive-care items are neither DFNA25-specific nor snippet-supportable. Process note from this round: an edit anchored on '- reference: PMID:34145196' matched inside an indented evidence block before reaching the top-level references: list, producing invalid YAML. Caught by running the validator rather than trusting the script's success. Anchor on a line-start pattern and assert the match count. Deliberately absent: no prevalence (nine probands worldwide), no phenotype frequency bands (no denominator that is DFNA25), no progression, no clinical_trials, no datasets. Ontology note: the deep-research report proposed HP:0012715 as 'Bilateral hearing impairment' (it is Profound hearing impairment) and HP:0002066 as 'Hearing impairment' (it is Gait ataxia). Both were caught by resolving through OLS and were not used. Validation: just validate exit 0 (65/65 snippets verified), just validate-terms exit 0, check-duplicate-keys / check-entity-refs / check-causal-targets all exit 0.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 35 citations 2026-09-01T20:20:31.017754

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Autosomal Dominant Nonsyndromic Hearing Loss 25
  • MONDO ID: MONDO:0011568 (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Autosomal Dominant Nonsyndromic Hearing Loss 25 covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.


1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Autosomal Dominant Nonsyndromic Hearing Loss 25 (DFNA25)

Executive summary

Autosomal dominant nonsyndromic hearing loss 25 (DFNA25) is a very rare, progressive, predominantly high-frequency sensorineural hearing loss caused by heterozygous pathogenic variants in SLC17A8, which encodes vesicular glutamate transporter 3 (VGLUT3/VGluT3). VGLUT3 loads glutamate into synaptic vesicles of cochlear inner hair cells (IHCs), enabling transmission from IHC ribbon synapses to type I spiral-ganglion neurons. Human evidence remains limited to a small number of families, so disease-specific prevalence, quantitative penetrance, progression rates, and quality-of-life statistics are not established. The strongest therapeutic evidence is preclinical: AAV-mediated VGLUT3 replacement has restored hearing in neonatal and adult Slc17a8-null mice, but no DFNA25-specific human gene-therapy trial or approved disease-modifying drug was identified.

The following table provides an ontology-ready synopsis.

domain established finding evidence type suggested ontology terms/IDs key evidence
disease identifier Autosomal Dominant Nonsyndromic Hearing Loss 25 (DFNA25) is a Mendelian deafness entity linked to SLC17A8 Human pedigree/genetic discovery MONDO:0011568; OMIM 605583 DFNA25 described as an "autosomal-dominant form of progressive, high-frequency nonsyndromic deafness" caused by SLC17A8 mutation (ruel2008impairmentofslc17a8 pages 1-2)
causal gene/protein SLC17A8 encodes vesicular glutamate transporter 3 (VGLUT3) Human, mouse, review SLC17A8; VGLUT3; OMIM 607557 VGLUT3 loads glutamate into inner hair cell synaptic vesicles before release to auditory nerve terminals (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2)
synonyms DFNA25; deafness, autosomal dominant 25; SLC17A8-related autosomal dominant nonsyndromic hearing loss Aggregated disease/gene nomenclature with primary literature support OMIM 605583; SLC17A8-related hearing loss Primary papers and reviews use DFNA25 / deafness, autosomal dominant 25 terminology (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2)
pathogenic variants Reported disease-associated variants include c.632C>T (p.A211V), p.M206Nfs*4, and c.763+1G>T Human genetic studies HGVS nomenclature where known; ACMG classification not uniformly published p.A211V segregated in two unrelated families and was absent in 267 controls; p.M206Nfs*4 absent in 100 controls; c.763+1G>T co-segregated in a 3-generation Korean family (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2, ryu2017identificationofa pages 1-6)
inheritance Inheritance is autosomal dominant Human pedigree HP:0000006 Autosomal dominant inheritance Multiple families showed autosomal-dominant segregation (ruel2008impairmentofslc17a8 pages 1-2, ryu2017identificationofa pages 1-6)
core phenotype Progressive high-frequency sensorineural hearing loss, nonsyndromic Human clinical HP:0000407 Sensorineural hearing impairment; HP:0002066 Hearing impairment; high-frequency qualifier if used in HPO mapping Human families had delayed/progressive high-frequency SNHL without syndromic features (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2)
onset/natural history Typically delayed/late onset with age-related penetrance increase and progression over time Human pedigree/clinical HPO terms for progressive hearing impairment; adult/late onset descriptors as appropriate DFNA phenotypes are described as delayed-onset and progressive; DFNA25 specifically showed age-related penetrance increase (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14, ryu2016screeningofthe pages 1-2)
syndromic status No consistent extra-auditory syndromic findings established Human clinical HP:0000007 Autosomal dominant inheritance; nonsyndromic descriptor Korean family report noted hearing loss was non-syndromic with no accompanying symptoms (ryu2017identificationofa pages 1-6)
primary anatomy Primary site is the cochlea, especially the organ of Corti inner hair cell synapse Human-mechanistic inference supported by mouse and expression data UBERON: cochlea; organ of Corti; inner hair cell VGLUT3 is selectively expressed in cochlear inner hair cells and mediates afferent transmission (ryu2016screeningofthe pages 1-2, ruel2008impairmentofslc17a8 pages 1-2)
affected cells Inner hair cells are primary; type I spiral ganglion neuron afferents are secondarily affected Mouse physiology/morphology with human disease relevance CL: inner hair cell; spiral ganglion neuron Slc17a8-null mice lacked acoustic auditory-nerve responses and later showed decline in afferent synapses and spiral ganglion neurons (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14)
subcellular localization VGLUT3 localizes to synaptic vesicle-like glutamatergic organelles/ribbon-synapse trafficking compartments in IHCs Proteomics, prior functional work GO cellular component: synaptic vesicle; presynaptic active zone; synaptic ribbon 2024 proteomics isolated "VGluT3-containing membrane vesicles" from IHCs and profiled ribbon-synapse trafficking machinery (cepeda2024proteomicanalysisreveals pages 1-3)
mechanism Impaired vesicular glutamate loading/release at the IHC ribbon synapse leads to failure of auditory nerve activation; downstream synapse and neuron loss can follow Human genetic inference plus mouse functional demonstration GO: glutamate transport; chemical synaptic transmission; synaptic vesicle cycle Null mice had absent acoustically evoked ABRs but preserved electrically evoked ABRs and otoacoustic emissions, supporting a synaptic glutamate-release defect rather than OHC failure (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14)
variant-specific mechanism The human p.A211V allele is modeled by mouse p.A224V and is associated with IHC stereocilia collapse, reduced summating potential, and oversized synaptic ribbons Mouse knock-in model of human allele GO: mechanotransduction; synaptic transmission; hair bundle organization Knock-in mice showed progressive hearing loss with intact cochlear amplification, IHC bundle collapse, and altered ribbon exocytosis, suggesting mechanotransduction failure followed by altered synaptic transfer (joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
diagnostic testing Diagnosis relies on audiologic evaluation plus molecular testing (single gene, deafness panel, WES/WGS depending context) Clinical genetics practice supported by gene-specific reports SLC17A8 sequencing; hereditary hearing loss panel SLC17A8 mutations were identified by candidate-gene sequencing and by whole-exome sequencing in affected families (ryu2016screeningofthe pages 1-2, ryu2017identificationofa pages 1-6)
electrophysiology ABR is abnormal from failed acoustic neural transmission; OAE/DPOAE may remain preserved when OHC function is intact Mouse functional evidence; clinically relevant inference ABR; otoacoustic emissions Slc17a8-null mice lacked auditory-nerve responses to sound yet retained robust otoacoustic emissions; p.A224V model had progressive ABR loss with intact DPOAEs (ruel2008impairmentofslc17a8 pages 1-2, joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
treatment status No DFNA25-specific approved molecular therapy identified; current real-world care is supportive/rehabilitative (hearing aids, cochlear implantation as indicated) Review plus mechanistic/animal evidence NCIT: Hearing Aid; Cochlear Implantation Reviews note hearing aids and cochlear implants remain standard care for hereditary deafness; SLC17A8-specific therapy remains preclinical (duhon2024genetherapyadvancements pages 4-5, zhang2024aav‐mediatedgenetherapy pages 3-4)
cochlear implant implication Because neural responses to electrical stimulation are preserved in Slc17a8-null mice, cochlear implantation is considered biologically plausible Mouse translational inference NCIT: Cochlear Implantation Electrically evoked ABRs were preserved in null mice, suggesting bypass of the defective IHC synapse may help (ruel2008impairmentofslc17a8 pages 13-14)
gene therapy/preclinical AAV1-VGLUT3 cochlear delivery rescued hearing in Vglut3 knockout mice; early postnatal RWM delivery achieved 100% normal ABR threshold recovery in one series Mouse preclinical interventional AAV gene replacement; VGLUT3 gene augmentation Akil 2012 reported normalized ABR thresholds within 2 weeks; P1-P3 RWM delivery rescued 19/19 mice and some maintained hearing long term (akil2012restorationofhearing pages 1-2, akil2012restorationofhearing pages 6-8)
mature-cochlea translational development 2023 mature-mouse CSF/cisterna magna delivery of AAV-PHP.B-CBA-VGLUT3-WPRE reportedly restored hearing in SLC17A8-/- mice except at 40 kHz Review summarizing preclinical primary study AAV-PHP.B; cisterna magna delivery 2024 review summarizes mature-mouse rescue at dose 2.27 × 10^11 vg with limited off-target expression reported (duhon2024genetherapyadvancements pages 11-12)
human trials status No human interventional trial specific to SLC17A8/DFNA25 was identified in the tool-based search Trial search / evidence gap ClinicalTrials.gov status: none identified for this gene-disease pair Recent reviews discuss human OTOF trials, not SLC17A8-specific trials; trial search returned no relevant SLC17A8 intervention (zhang2024aav‐mediatedgenetherapy pages 3-4, duhon2024genetherapyadvancements pages 4-5)
model organisms Key models are Slc17a8 knockout mice and VGLUT3A224V/A224V knock-in mice modeling human p.A211V Mouse in vivo models MGI/IMSR resources if needed; Slc17a8 mouse models Knockout demonstrates synaptic glutamate-release failure; knock-in models progressive/mechanosensory and synaptic pathology (ruel2008impairmentofslc17a8 pages 1-2, joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
comparative conservation The affected alanine residue is conserved across species and among human VGLUT paralogs Human/mouse comparative sequence evidence conserved residue annotation Conservation of A211 supported pathogenic relevance of p.A211V (ruel2008impairmentofslc17a8 pages 1-2)
epidemiology Disease-specific prevalence, incidence, sex ratio, and carrier frequency are not established in the retrieved DFNA25-specific literature Explicit data gap not available Available papers are family-based discovery/screening studies rather than population epidemiology (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2)
penetrance/expressivity Penetrance appears age-dependent and expressivity likely variable, but robust quantitative estimates are lacking Human pedigree with data gap age-dependent penetrance descriptor Human paper notes age-related penetrance increase; no precise percent penetrance estimate retrieved (ruel2008impairmentofslc17a8 pages 13-14)
environmental modifiers No DFNA25-specific environmental risk or protective modifiers were established in retrieved primary disease papers Explicit data gap not available Reviews discuss generic contributors to hearing loss (noise, aging), but not validated DFNA25-specific gene-environment interactions (ruel2008impairmentofslc17a8 pages 1-2, bottom2024defectsinhair pages 1-2)
QoL/prognosis gap No DFNA25-specific quality-of-life or life-expectancy studies were identified; morbidity is expected to derive mainly from chronic progressive hearing impairment Explicit data gap with general clinical inference hearing-disability QoL instruments if studied in future Family reports focus on hearing phenotype/genetics, not QoL or survival outcomes (ruel2008impairmentofslc17a8 pages 1-2, ryu2016screeningofthe pages 1-2)

Table: This table condenses the most actionable, ontology-ready facts for DFNA25/SLC17A8-related hearing loss, including core identifiers, phenotype, mechanism, models, and treatment status. It also flags major evidence gaps where disease-specific epidemiology, modifiers, and outcomes are not yet established.

1. Disease information

Definition and identifiers

DFNA25 is an inherited, nonsyndromic cochlear disorder characterized by progressive high-frequency sensorineural hearing impairment. The landmark report described it as an “autosomal-dominant form of progressive, high-frequency nonsyndromic deafness.” (ruel2008impairmentofslc17a8 pages 1-2)

  • Preferred name: Autosomal dominant nonsyndromic hearing loss 25
  • Synonyms: DFNA25; deafness, autosomal dominant 25; SLC17A8-related autosomal dominant nonsyndromic hearing loss
  • MONDO: MONDO:0011568
  • OMIM phenotype: 605583, DFNA25
  • Causal gene/protein: SLC17A8, VGLUT3; OMIM 607557
  • Locus: chromosome 12q21–q24.5 in the original linkage interval
  • ICD-10-CM: no DFNA25-specific code; generally coded under H90.3 (bilateral sensorineural hearing loss) or another audiometrically appropriate H90 category
  • ICD-11/MeSH: no uniquely specific DFNA25 entry was established in the retrieved literature; broader hereditary/sensorineural hearing-loss concepts apply.

The foundational human evidence came from pedigrees, clinical audiometry, linkage analysis, and germline DNA sequencing—not individual EHR-derived records. The broader identifiers and nomenclature are aggregated disease-level annotations.

The discovery article was published 8 August 2008 in the American Journal of Human Genetics, DOI 10.1016/j.ajhg.2008.07.008, PMID 18674745. Its abstract states: “We have identified SLC17A8…as the gene responsible for DFNA25.” (ruel2008impairmentofslc17a8 pages 1-2)

2. Etiology, risk, and protective factors

Causal factor

The primary cause is a heterozygous germline SLC17A8 variant affecting VGLUT3. The best-established allele, NM_139319.2:c.632C>T, p.(Ala211Val), segregated with hearing loss in two nominally unrelated families and was absent from 267 controls; linkage-disequilibrium analysis suggested distant common ancestry. The alanine is conserved across species and all three human VGLUT paralogs. (ruel2008impairmentofslc17a8 pages 1-2)

Additional reported alleles include:

  • p.(Met206AsnfsTer4): heterozygous frameshift predicted to terminate at residue 209 and remove transmembrane domains 5–12. It was found while screening 87 unrelated Korean patients with ADNSHL and was absent from 100 normal-hearing controls. The original authors described it as “likely” pathogenic; current ClinVar assertions should be checked at ingestion time rather than inferred from that wording. Publication: January 2016; DOI 10.1186/s12881-016-0269-3. (ryu2016screeningofthe pages 1-2)
  • c.763+1G>T: canonical splice-donor variant identified by WES in a three-generation Korean family. It was present in three affected relatives, absent from the tested unaffected relative and 100 normal-hearing controls, and was reported as probably pathogenic. Publication: September 2017; DOI 10.1016/j.gene.2017.06.040. (ryu2017identificationofa pages 23-25, ryu2017identificationofa pages 1-6)

These are germline, not somatic, variants. Population allele frequencies were not supplied in the retrieved primary evidence; contemporary gnomAD frequencies and transcript-normalized HGVS should be obtained directly before clinical interpretation.

Genetic mechanism and modifiers

Simple haploinsufficiency is unlikely to explain every DFNA25 allele: heterozygous Slc17a8 knockout mice have normal hearing and anatomy, whereas humans heterozygous for p.A211V develop age-dependent disease. This supports an allele-specific dominant-negative or toxic gain-of-function mechanism for p.A211V, although the precise molecular interaction remains unresolved. Truncating and splice variants may act differently, and pathogenicity should therefore be evaluated allele by allele. (ruel2008impairmentofslc17a8 pages 13-14)

No replicated modifier gene, protective SLC17A8 allele, epigenetic modifier, founder frequency, or germline-mosaicism estimate has been established. Family history is the major ascertainable risk factor; each child of a heterozygous affected person has a 50% transmission probability, although age-dependent penetrance complicates phenotype-based testing.

Environment and gene–environment interaction

Noise, aging, and ototoxic agents are established general causes or accelerants of cochlear synaptopathy, but no study has quantified a DFNA25-specific interaction. Recent work notes that genetic defects, loud noise, ototoxic drugs, and aging can all compromise IHC synaptic sound encoding. Consequently, noise and ototoxin avoidance is biologically reasonable but not proven to alter DFNA25 natural history. (bottom2024defectsinhair pages 1-2, cepeda2024proteomicanalysisreveals pages 1-3)

No specific diet, exercise program, supplement, vaccine, or medication has been demonstrated to prevent genetically initiated DFNA25.

3. Phenotypes

Core phenotype

The principal phenotype is bilateral, nonsyndromic, sensorineural hearing impairment, initially most prominent at high frequencies and progressive with age. Onset is generally delayed rather than congenital in the original p.A211V families, and penetrance rises with age. Severity and onset vary among carriers; robust percentages and annual threshold-shift estimates are unavailable. (ruel2008impairmentofslc17a8 pages 1-2, ruel2008impairmentofslc17a8 pages 13-14)

Suggested annotations are:

  • Sensorineural hearing impairment — HP:0000407
  • High-frequency hearing impairment — use the current HPO high-frequency term at database ingestion
  • Progressive hearing impairment — HP:0001730
  • Bilateral hearing impairment — HP:0012715
  • Autosomal dominant inheritance — HP:0000006
  • Adult/late onset — apply only when documented for the individual, because onset is variable

Preserved otoacoustic emissions and synaptic/auditory-neuropathy physiology are strongly demonstrated in mice, but should not automatically be entered as universal human phenotypes. In the null model, robust OAEs coexisted with absent sound-evoked auditory-nerve responses, localizing dysfunction downstream of outer-hair-cell amplification. (ruel2008impairmentofslc17a8 pages 1-2)

No consistent vestibular, visual, neurologic, renal, endocrine, craniofacial, or behavioral abnormality has been reported; a Korean pedigree specifically had no accompanying symptoms. (ryu2017identificationofa pages 1-6)

Functional and quality-of-life consequences

Disease-specific EQ-5D, SF-36, PROMIS, speech-recognition, educational, or employment data are unavailable. By clinical inference, progressive high-frequency loss can impair speech understanding—particularly consonants and speech in noise—communication, education, work, and social participation. These generic consequences should not be represented as measured DFNA25 outcomes.

4. Genetic and molecular information

SLC17A8 encodes a 589-amino-acid, predicted 12-transmembrane-domain major-facilitator-superfamily transporter. In cochlear IHCs, VGLUT3 packages glutamate into vesicles for release at ribbon synapses. (ryu2016screeningofthe pages 1-2)

Relevant molecular annotations include:

  • GO biological process: glutamate transmembrane transport; synaptic-vesicle loading; chemical synaptic transmission; synaptic-vesicle cycle; sensory perception of sound.
  • GO molecular function: vesicular glutamate transmembrane transporter activity.
  • GO cellular component: synaptic vesicle membrane; glutamatergic synapse; presynaptic active zone; ribbon synapse.
  • CHEBI: L-glutamate (CHEBI:29985).

No large recurrent deletion, inversion, translocation, aneuploidy, DNA-methylation signature, or disease-specific chromatin abnormality is established. Likewise, no validated prognostic transcriptomic, circulating, metabolomic, lipidomic, or epigenomic biomarker exists.

5. Environmental information

DFNA25 is not infectious, toxic, occupational, or lifestyle-caused. Environmental exposures may add independent cochlear injury to the inherited defect. Avoidable generic hazards include excessive sound, aminoglycosides when alternatives exist, cisplatin, and other recognized ototoxins. There is no evidence that smoking, alcohol, diet, exercise, radiation, pollution, or a pathogen specifically changes SLC17A8 penetrance.

A rat salicylate model found increased IHC VGLUT3 expression and tinnitus without a significant hearing-threshold difference, but this is acquired-toxicity evidence and does not establish salicylate as a DFNA25 modifier.

6. Mechanism and pathophysiology

Ordered causal chain

  1. A heterozygous pathogenic SLC17A8 lesion leads to altered amount, structure, trafficking, or function of VGLUT3 in cochlear IHCs.
  2. Altered VGLUT3 leads to defective glutamate accumulation in IHC synaptic vesicles; this is directly demonstrated for complete loss of VGLUT3 and inferred, with allele-specific complexities, for human dominant variants. (ruel2008impairmentofslc17a8 pages 12-13, ruel2008impairmentofslc17a8 pages 1-2)
  3. In the loss-of-function branch, empty or inadequately loaded vesicles can still undergo Ca²⁺-triggered exocytosis, but insufficient glutamate release results in failure to activate type I spiral-ganglion afferents. Vesicle turnover and exocytotic kinetics were initially preserved in null IHCs. (ruel2008impairmentofslc17a8 pages 12-13)
  4. In the p.A211V branch, the modeled mouse allele p.A224V leads to IHC stereociliary-bundle collapse and reduced receptor potential, followed by oversized ribbons and altered sustained exocytosis; these findings suggest primary mechano-transduction failure plus later synaptic dysfunction rather than pure transporter insufficiency. (joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
  5. Failed or distorted IHC-to-afferent signaling results in reduced auditory-nerve activity and elevated/absent acoustically evoked ABRs, while outer-hair-cell cochlear amplification may remain intact. (ruel2008impairmentofslc17a8 pages 1-2, joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
  6. Chronic loss of afferent activity leads to secondary decline of IHC afferent synapses, spiral-ganglion neurons, and lateral efferent endings; altered trophic support and activity-dependent circuit maturation are plausible mediators. (ruel2008impairmentofslc17a8 pages 12-13, ruel2008impairmentofslc17a8 pages 13-14)
  7. Tonotopically unequal vulnerability, not yet fully explained, results in the characteristic progressive high-frequency sensorineural hearing phenotype.

The principal upstream lesion is vesicular transporter dysfunction; mechano-transduction and ribbon abnormalities may be allele-specific parallel or downstream processes. Secondary neural/circuit degeneration is downstream. No primary immune, fibrotic, ischemic, endocrine, or metabolic mechanism has been demonstrated.

Suggested cell terms are inner hair cell, type I spiral-ganglion neuron, and secondarily lateral olivocochlear efferent neuron. Suggested anatomical terms are cochlea, organ of Corti, spiral ganglion, and IHC ribbon synapse. Exact CL/UBERON identifiers should be ontology-validated during curation.

Recent molecular profiling

A 2024 study used subcellular fractionation, anti-VGluT3 immunoisolation, label-free LC–MS, and imaging to generate the first broad proteomic inventory of native IHC trafficking organelles. It identified an age-dependent, mixed synaptic-vesicle/endosomal signature and enrichment after hearing onset of VAMP7, syntaxins 7/8/12–13, SCAMP1, V-ATPase, SV2, and PKCα. This profiles normal VGLUT3-positive organelles rather than DFNA25 patient tissue, but supplies an authoritative molecular framework for studying variant effects. Publication: February 2024; DOI 10.1016/j.mcpro.2023.100704. (cepeda2024proteomicanalysisreveals pages 1-3)

No DFNA25 patient-derived single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, organoid, iPSC, or CRISPR-screen dataset was identified.

7. Anatomical structures affected

  • Primary organ/system: inner ear/cochlea; auditory sensory system.
  • Primary tissue: sensory epithelium of the organ of Corti.
  • Primary cell: IHC, especially its apical stereociliary bundle for p.A211V-like disease and basolateral ribbon-synapse vesicular compartment for VGLUT3 function.
  • Secondary cells: IHC-afferent terminals and type I spiral-ganglion neurons; lateral efferent endings decline in null mice.
  • Relatively preserved structure: OHCs and cochlear amplification in the principal mouse models, reflected by robust OAE/DPOAE measurements. (ruel2008impairmentofslc17a8 pages 1-2, joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
  • Laterality: human disease is understood as bilateral; asymmetry is not a defining feature.

VGLUT3 is also expressed in selected central neurons, but DFNA25 is clinically nonsyndromic and no reproducible central-neurologic phenotype is established.

8. Temporal development

The human course is chronic and lifelong: high-frequency thresholds typically deteriorate progressively, with age-dependent clinical penetrance. There are no validated early/intermediate/end-stage definitions, median onset age, dB/year trajectory, spontaneous remissions, or episodic pattern. (ruel2008impairmentofslc17a8 pages 13-14)

The mouse evidence suggests two potentially important intervention windows. First, restoring neurotransmission before secondary spiral-ganglion loss should be advantageous. Second, treatment remains possible after auditory maturation: adult-mouse rescue has been reported, although delivery and neural preservation become more difficult. Neonatal mice are unusually permissive to AAV and do not directly model the fully developed human neonatal cochlea. (duhon2024genetherapyadvancements pages 11-12, duhon2024genetherapyadvancements pages 4-5)

9. Inheritance and population

Inheritance is autosomal dominant. Both sexes are expected to be affected equally and male-to-male transmission is possible. Penetrance appears age-dependent; no defensible percentage is available. Expressivity is variable, while anticipation has not been shown. Consanguinity is not etiologically important for this dominant condition.

A distant founder relationship was suggested for the two p.A211V families of Czech/German ancestry, but there is no population-wide founder-frequency estimate. Korean frameshift and splice variants demonstrate that DFNA25 is not confined to European ancestry. (ruel2008impairmentofslc17a8 pages 1-2, ryu2017identificationofa pages 1-6)

Disease-specific prevalence, incidence, carrier frequency, geographic distribution, sex ratio, and age distribution are unknown. The Korean screening study found one proposed frameshift allele among 87 unrelated ADNSHL probands, but this selected sample cannot be converted into population prevalence. For context only, the paper reported that roughly 70% of hereditary SNHL is nonsyndromic and that 10–20% of nonsyndromic cases follow dominant inheritance; these are not DFNA25-specific statistics. (ryu2016screeningofthe pages 1-2)

10. Diagnostics

Clinical evaluation

Recommended assessment includes otologic examination, family history over at least three generations, pure-tone air/bone audiometry, speech audiometry including speech-in-noise where available, tympanometry, and serial threshold monitoring. OAEs and ABR can help localize cochlear amplification versus IHC-synaptic/neural transmission, but no DFNA25-specific diagnostic cut-off exists.

Imaging is usually unnecessary in a classic bilateral hereditary presentation but may be appropriate for asymmetry, vestibular symptoms, cochlear-implant planning, or another suspected structural cause. Routine blood chemistry, biopsy, EEG, EMG, or metabolic testing does not diagnose DFNA25.

Genetic testing strategy

  1. Use a comprehensive hereditary-hearing-loss panel containing SLC17A8, with copy-number calling where technically validated.
  2. Use exome or genome sequencing when a panel is negative, the phenotype is atypical, or broader reanalysis is desirable. WES identified c.763+1G>T in the Korean pedigree. (ryu2017identificationofa pages 1-6)
  3. Confirm reportable variants by an orthogonal method as appropriate, evaluate segregation, and apply current ACMG/AMP and hearing-loss specifications.
  4. For a splice variant, RNA analysis can provide useful functional confirmation when an informative tissue or minigene assay is feasible.
  5. Once a familial pathogenic variant is established, use targeted testing for relatives, prenatal diagnosis, or preimplantation genetic testing.

CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not first-line tests for isolated, sequence-variant-mediated DFNA25 unless another diagnosis is suspected.

Differential diagnosis

The differential includes other progressive dominant nonsyndromic hearing losses—such as KCNQ4/DFNA2A, TECTA/DFNA8/12, WFS1/DFNA6/14/38, ACTG1/DFNA20/26, POU4F3/DFNA15, TMC1/DFNA36, and COCH/DFNA9—plus age/noise-related loss, ototoxicity, congenital infection, and structural disease. Vestibular dysfunction strongly suggests alternatives such as COCH-related disease. Molecular diagnosis is essential because audiograms overlap.

Newborn hearing screening can miss delayed-onset DFNA25. Children carrying a familial variant require scheduled audiologic surveillance even after a normal newborn screen.

11. Outcome and prognosis

DFNA25 is not known to reduce survival or life expectancy, and no disease-specific mortality is reported. Morbidity is auditory: progressive communication disability may eventually require amplification or implantation. Spontaneous biological recovery is not expected, although functional rehabilitation is often substantial.

Baseline severity, age of onset, serial threshold slope, speech recognition, and preservation of spiral-ganglion function are clinically relevant prognostic features. No molecular biomarker predicts progression beyond the familial variant and family-specific natural history. No five- or ten-year survival statistic is applicable.

12. Treatment and current implementation

Current care

There is no approved DFNA25-specific drug, RNA therapy, gene therapy, or pharmacogenomic guideline. Current management is individualized:

  • Hearing aids for aidable mild-to-severe loss—suggested NCIT annotation: Hearing Aid.
  • Assistive listening/remote-microphone systems, captioning, communication accommodations, and auditory rehabilitation.
  • Speech-language and educational support, especially for childhood onset.
  • Cochlear implantation for severe-to-profound loss or poor aided speech recognition—suggested NCIT annotation: Cochlear Implantation.

Cochlear implantation is mechanistically plausible because electrically evoked ABRs remained present in Slc17a8-null mice even when acoustic responses were absent, indicating that electrical stimulation can bypass the defective IHC synapse. This is translational inference, not a DFNA25-specific clinical outcome series. (ruel2008impairmentofslc17a8 pages 13-14)

Experimental gene replacement

In 2012, cochlear AAV1-VGLUT3 delivery to knockout mice produced IHC-selective protein expression and normalized ABR thresholds within two weeks. At postnatal days 1–3, round-window delivery rescued normal ABR thresholds in 19/19 mice; five followed for nine months retained normal thresholds. A 1-µL dose at 2.3×10¹³ vg/mL labeled 100% of IHCs, whereas 0.6 µL labeled about 40%; even partial IHC transduction could restore near-normal thresholds. Some rescued animals retained normal thresholds for up to 1.5 years, although neural counts and response amplitudes did not fully normalize. Publication: 26 July 2012, Neuron; DOI 10.1016/j.neuron.2012.05.019, PMID 22794260. (akil2012restorationofhearing pages 1-2, akil2012restorationofhearing pages 6-8, akil2012restorationofhearing pages 9-10)

A 2023 study summarized in a 2024 review delivered AAV-PHP.B-CBA-VGLUT3-WPRE into the cisterna magna of mice aged P28–P105. A dose of 2.27×10¹¹ vg reportedly restored hearing across tested frequencies except 40 kHz. Minimal brain expression and no liver expression were reported, but spinal-cord, dorsal-root-ganglion, and liver-vector-genome analyses were incomplete. The review appropriately highlights dorsal-root-ganglion toxicity seen in 83% of 213 nonhuman primates across other intracisternal AAV studies, making safety and species-specific tropism major translational barriers. (duhon2024genetherapyadvancements pages 11-12)

For dominant p.A211V-like disease, simple addition of wild-type SLC17A8 may not suppress a dominant-negative/toxic mutant allele. Mutation-agnostic silencing plus replacement, allele-specific silencing, or editing may ultimately be required; none has yet been validated clinically for DFNA25.

Recent expert reviews conclude that VGLUT3 replacement is among the most successful preclinical hearing-loss programs, sometimes restoring wild-type ABR thresholds, but emphasize poorer adult transduction and incomplete ABR wave-I/neural rescue. One review contrasts approximately 100% IHC/~75% spiral-ganglion-neuron transduction in neonatal mice with 100% IHC but <20% SGN transduction in adults. (duhon2024genetherapyadvancements pages 4-5)

A search of ClinicalTrials.gov found no SLC17A8/DFNA25-specific human interventional trial. Human hereditary-deafness gene-therapy trials described in the 2024 literature concern chiefly OTOF/DFNB9, not DFNA25. (zhang2024aav‐mediatedgenetherapy pages 3-4)

13. Prevention

Primary prevention of a de novo or inherited pathogenic allele is not possible through lifestyle change. Reproductive options after molecular diagnosis include genetic counseling, natural conception with or without prenatal diagnosis, donor gametes, adoption, and IVF with preimplantation genetic testing.

Secondary prevention comprises cascade testing and longitudinal audiology, particularly because phenotype-based screening may miss young, age-dependent carriers. Early amplification and educational intervention can reduce developmental and communication consequences.

Tertiary prevention includes hearing conservation, avoidance of unnecessary ototoxic exposure, optimized amplification, vaccination and infection prevention according to routine standards—especially before cochlear implantation—and maintenance of social/communication access. These measures prevent additive injury or complications; they do not correct SLC17A8.

14. Other species and natural disease

Orthologous Slc17a8 is conserved across vertebrates, and the p.A211 residue is conserved across species. Suggested taxa include Mus musculus (NCBI Taxonomy 10090), Rattus norvegicus (10116), Danio rerio (7955), and Homo sapiens (9606). (ruel2008impairmentofslc17a8 pages 1-2)

No well-validated, naturally occurring companion-animal or livestock counterpart attributable to an orthologous dominant SLC17A8 allele was identified; therefore no defensible VBO breed annotation or veterinary prevalence can be assigned. DFNA25 is noninfectious and has no zoonotic or cross-species transmission potential.

15. Model organisms

Slc17a8 knockout mouse

Targeted exon-2 deletion produces congenital profound deafness with absent acoustic auditory-nerve responses, preserved electrically evoked ABRs, and robust OAEs. Ca²⁺-triggered vesicle turnover remains intact at approximately two weeks, demonstrating that vesicle fusion can occur without glutamate loading. Afferent synapses, spiral-ganglion neurons, and lateral efferent terminals decline later. This model is excellent for transporter loss and gene-replacement studies but does not reproduce heterozygous, delayed-onset human p.A211V disease. (ruel2008impairmentofslc17a8 pages 12-13, ruel2008impairmentofslc17a8 pages 1-2)

p.A224V knock-in mouse

Mouse p.A224V models human p.A211V. Homozygous knock-in mice exhibit progressive ABR loss with preserved cochlear amplification, reduced summating potentials, IHC—but not OHC—stereociliary-bundle collapse, oversized ribbons, and increased sustained-pool exocytosis. The authors concluded that DFNA25 “stems from a failure in the mechano-transduction followed by a change in synaptic transfer.” Publication: December 2021; DOI 10.1113/JP282181. The homozygous design may exaggerate a heterozygous human phenotype. (joshi2021vglut3‐p.a211vvariantfuses pages 1-2)

Other model uses and limitations

VGLUT3-positive IHC organelle immunoisolation and cochlear explants support biochemical and cellular studies; zebrafish offer conserved hair-cell biology and regeneration but differ from mammalian cochlear frequency tuning and OHC specialization. No validated DFNA25 patient iPSC-derived IHC or cochlear-organoid model was identified.

Evidence appraisal and principal knowledge gaps

The causal gene–disease relationship is strong: linkage and segregation in human families align with highly specific knockout and knock-in physiology. Nevertheless, the clinical evidence base is small and family-biased. Major missing items are disease-specific prevalence, quantitative penetrance, variant-level natural history, prospective speech and quality-of-life outcomes, human cochlear-implant outcomes, validated environmental modifiers, patient-derived omics, and clinical therapeutic trials. The most important translational distinction is that successful replacement in a recessive/null mouse does not prove efficacy against a dominant human missense allele.

Key source list

  1. Ruel J, et al. Am J Hum Genet. Published 8 August 2008. DOI: 10.1016/j.ajhg.2008.07.008; PMID 18674745. (ruel2008impairmentofslc17a8 pages 1-2)
  2. Akil O, et al. Neuron. Published 26 July 2012. DOI: 10.1016/j.neuron.2012.05.019; PMID 22794260. (akil2012restorationofhearing pages 1-2)
  3. Ryu N, et al. BMC Medical Genetics. January 2016. DOI: 10.1186/s12881-016-0269-3. (ryu2016screeningofthe pages 1-2)
  4. Ryu N, et al. Gene. September 2017. DOI: 10.1016/j.gene.2017.06.040. (ryu2017identificationofa pages 1-6)
  5. Joshi Y, et al. Journal of Physiology. December 2021. DOI: 10.1113/JP282181. (joshi2021vglut3‐p.a211vvariantfuses pages 1-2)
  6. Cepeda AP, et al. Molecular & Cellular Proteomics. February 2024. DOI: 10.1016/j.mcpro.2023.100704. (cepeda2024proteomicanalysisreveals pages 1-3)
  7. Duhon BH, et al. Frontiers in Audiology and Otology. July 2024. DOI: 10.3389/fauot.2024.1423853. (duhon2024genetherapyadvancements pages 11-12, duhon2024genetherapyadvancements pages 4-5)
  8. Zhang L, et al. Advanced Science. November 2024. DOI: 10.1002/advs.202402166. (zhang2024aav‐mediatedgenetherapy pages 3-4)

References

  1. (ruel2008impairmentofslc17a8 pages 1-2): Jérôme Ruel, Sarah Emery, Régis Nouvian, Tiphaine Bersot, Bénédicte Amilhon, Jana M. Van Rybroek, Guy Rebillard, Marc Lenoir, Michel Eybalin, Benjamin Delprat, Theru A. Sivakumaran, Bruno Giros, Salah El Mestikawy, Tobias Moser, Richard J.H. Smith, Marci M. Lesperance, and Jean-Luc Puel. Impairment of slc17a8 encoding vesicular glutamate transporter-3, vglut3, underlies nonsyndromic deafness dfna25 and inner hair cell dysfunction in null mice. American journal of human genetics, 83 2:278-92, Aug 2008. URL: https://doi.org/10.1016/j.ajhg.2008.07.008, doi:10.1016/j.ajhg.2008.07.008. This article has 345 citations and is from a highest quality peer-reviewed journal.

  2. (ryu2016screeningofthe pages 1-2): Nari Ryu, Borum Sagong, Hong-Joon Park, Min-A Kim, Kyu-Yup Lee, Jae Young Choi, and Un-Kyung Kim. Screening of the slc17a8 gene as a causative factor for autosomal dominant non-syndromic hearing loss in koreans. BMC Medical Genetics, Jan 2016. URL: https://doi.org/10.1186/s12881-016-0269-3, doi:10.1186/s12881-016-0269-3. This article has 26 citations and is from a peer-reviewed journal.

  3. (ryu2017identificationofa pages 1-6): Nari Ryu, Seokwon Lee, Hong-Joon Park, Byeonghyeon Lee, Tae-Jun Kwon, Jinwoong Bok, Chan Ik Park, Kyu-Yup Lee, Jeong-In Baek, and Un-Kyung Kim. Identification of a novel splicing mutation within slc17a8 in a korean family with hearing loss by whole-exome sequencing. Gene, 627:233-238, Sep 2017. URL: https://doi.org/10.1016/j.gene.2017.06.040, doi:10.1016/j.gene.2017.06.040. This article has 16 citations and is from a peer-reviewed journal.

  4. (ruel2008impairmentofslc17a8 pages 13-14): Jérôme Ruel, Sarah Emery, Régis Nouvian, Tiphaine Bersot, Bénédicte Amilhon, Jana M. Van Rybroek, Guy Rebillard, Marc Lenoir, Michel Eybalin, Benjamin Delprat, Theru A. Sivakumaran, Bruno Giros, Salah El Mestikawy, Tobias Moser, Richard J.H. Smith, Marci M. Lesperance, and Jean-Luc Puel. Impairment of slc17a8 encoding vesicular glutamate transporter-3, vglut3, underlies nonsyndromic deafness dfna25 and inner hair cell dysfunction in null mice. American journal of human genetics, 83 2:278-92, Aug 2008. URL: https://doi.org/10.1016/j.ajhg.2008.07.008, doi:10.1016/j.ajhg.2008.07.008. This article has 345 citations and is from a highest quality peer-reviewed journal.

  5. (cepeda2024proteomicanalysisreveals pages 1-3): Andreia P. Cepeda, Momchil Ninov, Jakob Neef, Iwan Parfentev, Kathrin Kusch, Ellen Reisinger, Reinhard Jahn, Tobias Moser, and Henning Urlaub. Proteomic analysis reveals the composition of glutamatergic organelles of auditory inner hair cells. Feb 2024. URL: https://doi.org/10.1016/j.mcpro.2023.100704, doi:10.1016/j.mcpro.2023.100704. This article has 12 citations and is from a domain leading peer-reviewed journal.

  6. (joshi2021vglut3‐p.a211vvariantfuses pages 1-2): Yuvraj Joshi, Chloé P. Petit, Stéphanie Miot, Marie Guillet, Gaston Sendin, Jérôme Bourien, Jing Wang, Rémy Pujol, Salah El Mestikawy, Jean‐Luc Puel, and Régis Nouvian. Vglut3‐p.a211v variant fuses stereocilia bundles and elongates synaptic ribbons. Dec 2021. URL: https://doi.org/10.1113/jp282181, doi:10.1113/jp282181. This article has 12 citations.

  7. (duhon2024genetherapyadvancements pages 4-5): Bailey H. Duhon, Eric C. Bielefeld, Yin Ren, and Jerusha Naidoo. Gene therapy advancements for the treatment of acquired and hereditary hearing loss. Frontiers in Audiology and Otology, Jul 2024. URL: https://doi.org/10.3389/fauot.2024.1423853, doi:10.3389/fauot.2024.1423853. This article has 9 citations.

  8. (zhang2024aav‐mediatedgenetherapy pages 3-4): Liyan Zhang, Fangzhi Tan, Jieyu Qi, Yicheng Lu, Xiaohan Wang, Xuehan Yang, Xiangyan Chen, Xinru Zhang, Jinyi Fan, Yinyi Zhou, Li Peng, Nianci Li, Lei Xu, Shiming Yang, and Renjie Chai. Aav‐mediated gene therapy for hereditary deafness: progress and perspectives. Advanced Science, Nov 2024. URL: https://doi.org/10.1002/advs.202402166, doi:10.1002/advs.202402166. This article has 41 citations and is from a peer-reviewed journal.

  9. (akil2012restorationofhearing pages 1-2): Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, and Lawrence R. Lustig. Restoration of hearing in the vglut3 knockout mouse using virally mediated gene therapy. Neuron, 75:283-293, Jul 2012. URL: https://doi.org/10.1016/j.neuron.2012.05.019, doi:10.1016/j.neuron.2012.05.019. This article has 480 citations and is from a highest quality peer-reviewed journal.

  10. (akil2012restorationofhearing pages 6-8): Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, and Lawrence R. Lustig. Restoration of hearing in the vglut3 knockout mouse using virally mediated gene therapy. Neuron, 75:283-293, Jul 2012. URL: https://doi.org/10.1016/j.neuron.2012.05.019, doi:10.1016/j.neuron.2012.05.019. This article has 480 citations and is from a highest quality peer-reviewed journal.

  11. (duhon2024genetherapyadvancements pages 11-12): Bailey H. Duhon, Eric C. Bielefeld, Yin Ren, and Jerusha Naidoo. Gene therapy advancements for the treatment of acquired and hereditary hearing loss. Frontiers in Audiology and Otology, Jul 2024. URL: https://doi.org/10.3389/fauot.2024.1423853, doi:10.3389/fauot.2024.1423853. This article has 9 citations.

  12. (bottom2024defectsinhair pages 1-2): Riley T. Bottom, Yijun Xu, Caroline Siebald, Jinsei Jung, and Ulrich Müller. Defects in hair cells disrupt the development of auditory peripheral circuitry. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-55275-x, doi:10.1038/s41467-024-55275-x. This article has 7 citations and is from a highest quality peer-reviewed journal.

  13. (ryu2017identificationofa pages 23-25): Nari Ryu, Seokwon Lee, Hong-Joon Park, Byeonghyeon Lee, Tae-Jun Kwon, Jinwoong Bok, Chan Ik Park, Kyu-Yup Lee, Jeong-In Baek, and Un-Kyung Kim. Identification of a novel splicing mutation within slc17a8 in a korean family with hearing loss by whole-exome sequencing. Gene, 627:233-238, Sep 2017. URL: https://doi.org/10.1016/j.gene.2017.06.040, doi:10.1016/j.gene.2017.06.040. This article has 16 citations and is from a peer-reviewed journal.

  14. (ruel2008impairmentofslc17a8 pages 12-13): Jérôme Ruel, Sarah Emery, Régis Nouvian, Tiphaine Bersot, Bénédicte Amilhon, Jana M. Van Rybroek, Guy Rebillard, Marc Lenoir, Michel Eybalin, Benjamin Delprat, Theru A. Sivakumaran, Bruno Giros, Salah El Mestikawy, Tobias Moser, Richard J.H. Smith, Marci M. Lesperance, and Jean-Luc Puel. Impairment of slc17a8 encoding vesicular glutamate transporter-3, vglut3, underlies nonsyndromic deafness dfna25 and inner hair cell dysfunction in null mice. American journal of human genetics, 83 2:278-92, Aug 2008. URL: https://doi.org/10.1016/j.ajhg.2008.07.008, doi:10.1016/j.ajhg.2008.07.008. This article has 345 citations and is from a highest quality peer-reviewed journal.

  15. (akil2012restorationofhearing pages 9-10): Omar Akil, Rebecca P. Seal, Kevin Burke, Chuansong Wang, Aurash Alemi, Matthew During, Robert H. Edwards, and Lawrence R. Lustig. Restoration of hearing in the vglut3 knockout mouse using virally mediated gene therapy. Neuron, 75:283-293, Jul 2012. URL: https://doi.org/10.1016/j.neuron.2012.05.019, doi:10.1016/j.neuron.2012.05.019. This article has 480 citations and is from a highest quality peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 12
Resolved 12
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 12
On topic 5
Off topic 1

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

  • PMID:22794260 (1 mention) - Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons.
  • shared terms: none

Weighed against this report's own most characteristic terms: disease, human, dfna25, clinical, gene, loss, hearing, genetic, model, variant, slc17a8, dominant, cochlear, molecular, phenotype, allele, type, nonsyndromic, progressive, ihc.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 8
Resolved 8
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 1
Terms named correctly 0
Terms named as a different term 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0011568 (3 mentions) - the report calls it "if available"; MONDO calls it autosomal dominant nonsyndromic hearing loss 25